

This Page Is Inserted by IFW Operations
and is not a part of the Official Record

BEST AVAILABLE IMAGES

Defective images within this document are accurate representations of the original documents submitted by the applicant.

Defects in the images may include (but are not limited to):

- BLACK BORDERS
- TEXT CUT OFF AT TOP, BOTTOM OR SIDES
- FADED TEXT
- ILLEGIBLE TEXT
- SKEWED/SLANTED IMAGES
- COLORED PHOTOS
- BLACK OR VERY BLACK AND WHITE DARK PHOTOS
- GRAY SCALE DOCUMENTS

IMAGES ARE BEST AVAILABLE COPY.

**As rescanning documents *will not* correct images,
please do not report the images to the
Image Problem Mailbox.**

(19) World Intellectual Property Organization
International Bureau



(43) International Publication Date
1 March 2001 (01.03.2001)

PCT

(10) International Publication Number
WO 01/14538 A2

(51) International Patent Classification⁷: C12N 15/00

(21) International Application Number: PCT/US00/22613

(22) International Filing Date: 11 August 2000 (11.08.2000)

(25) Filing Language: English

(26) Publication Language: English

(30) Priority Data:
60/151,224 26 August 1999 (26.08.1999) US
60/172,128 17 December 1999 (17.12.1999) US

(71) Applicant: CALGENE LLC [US/US]; 1920 Fifth Street,
Davis, CA 95616 (US).

(72) Inventor: FILLATTI, Joanne, J.; 36757 Russell Blvd.,
Davis, CA 95616 (US).

(74) Agent: EAGLE, Alissa, M.; Calgene LLC, 1920 Fifth
Street, Davis, CA 95616 (US).

(81) Designated States (*national*): AL, AM, AT, AU, AZ, BA, BB, BG, BR, BY, CA, CH, CN, CU, CZ, DE, DK, EE, ES, FI, GB, GD, GE, GH, GM, HR, HU, ID, IL, IN, IS, JP, KE, KG, KP, KR, KZ, LC, LK, LR, LS, LT, LU, LV, MD, MG, MK, MN, MW, MX, NO, NZ, PL, PT, RO, RU, SD, SE, SG, SI, SK, SL, TJ, TM, TR, TT, UA, UG, UZ, VN, YU, ZW.

(84) Designated States (*regional*): European patent (AT, BE, CH, CY, DE, DK, ES, FI, FR, GB, GR, IE, IT, LU, MC, NL, PT, SE).

Published:
— Without international search report and to be republished upon receipt of that report.

For two-letter codes and other abbreviations, refer to the "Guidance Notes on Codes and Abbreviations" appearing at the beginning of each regular issue of the PCT Gazette.

(54) Title: NUCLEIC ACID SEQUENCES AND METHODS OF USE FOR THE PRODUCTION OF PLANTS WITH MODIFIED POLYUNSATURATED FATTY ACIDS

(57) Abstract: By this invention, novel nucleic acid sequences are provided, wherein said nucleic acid sequence is a genomic sequence of a plant desaturase encoding sequence. Also provided in the present invention are the promoter and intron sequences of the desaturase genomic sequences. Furthermore, recombinant DNA constructs employing the polynucleotide sequences are provided. The instant invention also provides methods for the modification of fatty acid compositions in host plant cells.

WO 01/14538 A2

**NUCLEIC ACID SEQUENCES AND METHODS OF USE FOR THE
PRODUCTION OF PLANTS WITH MODIFIED POLYUNSATURATED FATTY
ACIDS**

5

INTRODUCTION

This application claims priority to U.S. Provisional Application Serial No. 60/151,224 filed August 26, 1999 and U.S. Provisional Application Serial No. 60/172,128 filed December 17, 1999.

10

Technical Field

The present invention is directed to nucleic acid sequences and constructs, and methods related thereto.

15 Background

Plant oils are used in a variety of applications. Novel vegetable oils compositions and/or improved means to obtain oils compositions, from biosynthetic or natural plant sources, are needed. Depending upon the intended oil use, various different fatty acid compositions are desired.

20

One means postulated to obtain such oils and/or modified fatty acid compositions is through the genetic engineering of plants. However, it is necessary to identify the appropriate nucleic acid sequences which are capable of producing the desired phenotypic result, regulatory regions capable of directing the correct application of such sequences, and the like.

Higher plants appear to synthesize fatty acids via a common metabolic pathway (fatty acid synthetase pathway). In developing seeds, where fatty acids are attached to glycerol backbones, forming triglycerides, for storage as a source of energy for further germination, the FAS pathway is located in the proplastids. The first committed step is the formation of acetyl-ACP (acyl carrier protein) from acetyl-CoA and ACP catalyzed by the enzyme, acetyl-CoA:ACP transacylase (ATA). Elongation of acetyl-ACP to 16- and 18- carbon fatty acids involves the cyclical action of the following sequence of reactions: condensation with a two-carbon unit from malonyl-ACP to form a β -ketoacyl-ACP (β -ketoacyl-ACP synthase), reduction of the keto-function to an alcohol (β -ketoacyl-ACP reductase), dehydration to form an enoyl-ACP (β -hydroxyacyl-ACP dehydrase), and finally reduction of the enoyl-ACP to form the elongated saturated acyl-ACP (enoyl-ACP reductase). β -ketoacyl-ACP synthase I, catalyzes elongation up to palmitoyl-ACP (C16:0), whereas β -ketoacyl-ACP synthase II catalyzes the final elongation to stearyl-ACP (C18:0). Common plant unsaturated fatty acids, such as oleic, linoleic and α -linolenic acids found in storage triglycerides, originate from the desaturation of stearyl-ACP to form oleoyl-ACP (C18:1) in a reaction catalyzed by a soluble plastid Δ -9 desaturase (also often referred to as "stearyl-ACP desaturase"). Molecular oxygen is required for desaturation in which reduced ferredoxin serves as an electron co-donor. Additional desaturation is effected sequentially by the actions of membrane bound Δ -12 desaturase and Δ -15 desaturase. These "desaturases" thus create mono- or polyunsaturated fatty acids respectively.

Obtaining nucleic acid sequences capable of producing a phenotypic result in FAS, desaturation and/or incorporation of fatty acids into a glycerol backbone to produce an oil is subject to various obstacles including but not limited to the identification of metabolic factors of interest, choice and characterization of an enzyme source with useful

kinetic properties, purification of the protein of interest to a level which will allow for its amino acid sequencing, utilizing amino acid sequence data to obtain a nucleic acid sequence capable of use as a probe to retrieve the desired DNA sequence, and the preparation of constructs, transformation and analysis of the resulting plants.

5 Thus, additional nucleic acid targets and methods for modifying fatty acid compositions are needed. In particular, constructs and methods to produce a variety of ranges of different fatty acid compositions are needed.

SUMMARY OF THE INVENTION

10

The present invention is generally directed to genomic desaturase polynucleotides, and in particular to genomic desaturase polynucleotides which encode enzymes that catalyze the insertion of a double bond into a fatty acyl moiety at the twelfth ($\Delta 12$ desaturase or fad2) or fifteenth ($\Delta 15$ desaturase or fad3) carbon position in a fatty acyl chain as counted from the carboxyl terminus. Further, the present invention provides isolated non-coding regions of such genomic polynucleotide sequences, particularly including the introns, and promoter regions. Specific oligonucleotides are provided which include partial or complete sequences which are derived from $\Delta 12$ and $\Delta 15$ desaturase promoter and intron sequences. Although the sequences disclosed herein are obtained from soybean plants, it is contemplated that additional sequences can be derived from intron and promoter regions of desaturase genomic polynucleotide sequences which are homologous or have identity to the soybean desaturase sequences. Such additional desaturase sequences can be obtained using standard methods described below from a variety of plant sources, in particular oilseed crops.

15

20

It is also an aspect of the present invention to provide recombinant DNA constructs which can be used for the modification of the fatty acid composition in a plant and in particular, to modify the transcription or transcription and translation (expression) of desaturase genes or proteins, such as $\Delta 12$ and $\Delta 15$ desaturase. The invention is particularly directed to DNA constructs which include sequences which are derived from the intron or promoter regions of a genomic clone wherein said sequences are in a sense or antisense orientation in a DNA construct. These DNA constructs are then used to transform or transfect host cells to produce plants with modified levels of fatty acids, particularly modified levels of oleic, linoleic and linolenic acid. It is particularly contemplated to provide constructs and methods for down regulating $\Delta 12$ and $\Delta 15$ desaturase gene expression, so as to increase the levels of oleic acid and to decrease the levels of linoleic acid and linolenic acid. It is particularly contemplated to alter the fatty acid composition in seed tissue of oilseed crops.

The modified plant cells, plants, seeds and oils obtained by the expression of the $\Delta 12$ and $\Delta 15$ desaturase polynucleotides are also considered part of the invention. Further, it is contemplated to produce oil compositions with specific relative levels of each fatty acid. One preferred embodiment comprises at least about 80 - 85% oleic acid, no more than about 1 - 2% linoleic acid, and no more than about 1 - 3% linolenic acid; and a second preferred embodiment comprising at least about 50-75% oleic acid, at least about 10 - 30% linoleic acid, and no more than about 3% linolenic acid.

DETAILED DESCRIPTION OF THE INVENTION

The present invention is directed to genomic desaturase sequences, particularly the isolated non-coding sequences from genomic fatty acid desaturase nucleic acid sequences from host cell sources. A desaturase sequence of this invention includes any nucleic acid

genomic sequence, including all non-coding regions, encoding amino acids from a source, such as a protein, polypeptide or peptide, obtainable from a cell source, which is capable of catalyzing the insertion of a double bond into a fatty acyl moiety in a plant host cell, i.e., in vivo, or in a plant cell-like environment, i.e. in vitro. As will be described in more detail below, specific genomic polynucleotide sequences encoding enzymes which add double bonds at the twelfth ($\Delta 12$ desaturase) and fifteenth ($\Delta 15$ desaturase) carbon positions in a fatty acyl chain as counted from the carboxyl terminus are provided. In addition, provided herein are specific non-coding regions of such genomic sequences.

The term “non-coding” refers to sequences of polynucleotides that do not encode part or all of an expressed protein. Non-coding sequences include but are not limited to introns, promoter regions, and 5' untranslated regions.

The term “intron” as used herein refers to the normal sense of the term as meaning a segment of polynucleotides, usually DNA, that does not encode part or all of an expressed protein.

The term “exon” as used herein refers to the normal sense of the term as meaning a segment of polynucleotides, usually DNA, that encodes part or all of an expressed protein.

Thus, the term “intron” refers to gene regions that are transcribed into RNA molecules, but which are spliced out of the RNA before the RNA is translated into a protein. As contrasted to the term “exon” which refers to gene regions that are transcribed into RNA and subsequently translated into proteins.

As set forth in detail in the sequence listing and the examples, genomic $\Delta 12$ desaturase and $\Delta 15$ desaturase sequences and intron and promoter regions obtained from such sequences are provided herein. In particular, two $\Delta 12$ desaturase genomic clones

were identified and are set forth in SEQ ID NOs:1 and 23. A single $\Delta 15$ desaturase genomic clone was identified and is set forth in SEQ ID NO:3. A single intron region was obtained from each of the $\Delta 12$ desaturase genomic clones with the sequences provided in SEQ ID NOs:2 and 24, respectively. The promoter region from each of the $\Delta 12$ desaturase genomic clones are respectively included in SEQ ID NO:1 (base pairs 1 - 1094) and SEQ ID NO:23 (base pairs 1 - 1704). The $\Delta 15$ desaturase included seven introns in the coding region (set forth as SEQ ID NOs:4, 5, 6, 7, 8, 25 and 26). In addition, preliminary results suggest that there is an additional intron within the 5' untranslated region.

Although the sequences described herein are obtained from soybean, it is contemplated that intron and promoter regions can be obtained from desaturase genomic polynucleotide sequences which are homologous or have identity to the soybean desaturase sequences. In particular, sequences can be obtained from other plant sources and particularly from oilseed crops. Such genomic sequences can be obtained using standard methods, certain of which are described below.

The sequences of the present invention can be used to modify the fatty acid composition in a plant (see Example 3 and Table I). In particular, it is shown that sense and antisense suppression can be used to obtain broad ranges in the levels of oleic, linoleic and linolenic acid. In particular, it is shown that levels of oleic acid can range from about 26 to 80 %, levels of linoleic acid can range from about 2.97 to 49.92 % and levels of linolenic acid can range from about 3.38 to 8.81%. However, these are merely representative of the broad range that be can achieved. Moreover, it is contemplated that combinations of the sequences could be used to achieve additional fatty acid compositions. Certain compositions are preferred based on the intended use of the oil.

One preferred composition includes at least about 50 - 75% oleic acid, at least about 10 - 30% linoleic acid and no more than about 3% linolenic acid. A particularly preferred embodiment includes at least about 60 - 70% oleic acid, at least about 15 - 20% linoleic acid and no more than about 3% linolenic acid.

5 Although the examples set forth herein utilize sense or antisense suppression to downregulate the gene of interest, it is contemplated that other means of modifying gene expression can be used. In particular, it is contemplated that gene expression can be down regulated using DNA binding proteins which can be designed to specifically bind to the non-coding regions identified herein or that ribozymes can be designed to cleave such
10 non-coding regions. In addition, as described below, other methods of downregulation of gene expression which are well known in the art are contemplated and can be used with the sequences of the present invention.


Isolated Polynucleotides, Proteins, and Polypeptides

15 A first aspect of the present invention relates to isolated desaturase polynucleotides. The polynucleotide sequences of the present invention include isolated polynucleotides that are obtainable from genomic nucleic acid sequences.

 The invention provides a polynucleotide sequence identical over its entire length
20 to each sequence as set forth in the Sequence Listing. The polynucleotide includes non-coding sequences, including for example, but not limited to, non-coding 5' and 3' sequences, such as the transcribed, untranslated sequences, termination signals, ribosome binding sites, sequences that stabilize mRNA, introns, polyadenylation signals, and additional coding sequence that encodes additional amino acids. For example, a marker
25 sequence can be included to facilitate the purification of the fused polypeptide.

Polynucleotides of the present invention also include polynucleotides comprising a structural gene and the naturally associated sequences that control gene expression.

The invention also includes polynucleotides of the formula:



5 wherein, at the 5' end, X is hydrogen, and at the 3' end, Y is hydrogen or a metal, R_1 and R_3 are any nucleic acid residue, n is an integer between 1 and 3000, preferably between 1 and 1000 and R_2 is a nucleic acid sequence of the invention, particularly a nucleic acid sequence selected from the group set forth in the Sequence Listing and preferably SEQ ID NOs: 1 - 8, and 23 - 29. In the formula, R_2 is oriented so that its 5' end residue is at the
10 left, bound to R_1 , and its 3' end residue is at the right, bound to R_3 . Any stretch of nucleic acid residues denoted by either R group, where R is greater than 1, may be either a heteropolymer or a homopolymer, preferably a heteropolymer.

Further preferred embodiments of the invention that are at least 50%, 60%, or 70% identical over their entire length to a polynucleotide of the invention, and polynucleotides
15 that are complementary to such polynucleotides. More preferable are polynucleotides that comprise a region that is at least 80% identical over its entire length to a polynucleotide of the invention and polynucleotides that are complementary thereto. In this regard, polynucleotides at least 90% identical over their entire length are particularly preferred, those at least 95% identical are especially preferred. Further, those with at least 97%
20 identity are highly preferred and those with at least 98% and 99% identity are particularly highly preferred, with those at least 99% being the most highly preferred.

Preferred embodiments are polynucleotides that are obtained from genomic polynucleotide sequences and set forth in the Sequence Listing.

The invention further relates to polynucleotides that hybridize to the above-
25 described sequences. In particular, the invention relates to polynucleotides that hybridize

under stringent conditions to the above-described polynucleotides. As used herein, the terms "stringent conditions" and "stringent hybridization conditions" mean that hybridization will generally occur if there is at least 95% and preferably at least 97% identity between the sequences. An example of stringent hybridization conditions is

5 overnight incubation at 42°C in a solution comprising 50% formamide, 5x SSC (150 mM NaCl, 15 mM trisodium citrate), 50 mM sodium phosphate (pH 7.6), 5x Denhardt's solution, 10% dextran sulfate, and 20 micrograms/milliliter denatured, sheared salmon sperm DNA, followed by washing the hybridization support in 0.1x SSC at approximately 65°C. Other hybridization and wash conditions are well known and are exemplified in
10 Sambrook, *et al.*, Molecular Cloning: A Laboratory Manual, Second Edition, Cold Spring Harbor, NY (1989), particularly Chapter 11.

The invention also provides a polynucleotide consisting essentially of a polynucleotide sequence obtainable by screening an appropriate library containing the complete gene for a polynucleotide sequence set forth in the Sequence Listing under
15 stringent hybridization conditions with a probe having the sequence of said polynucleotide sequence or a fragment thereof; and isolating said polynucleotide sequence. Fragments useful for obtaining such a polynucleotide include, for example, probes and primers as described herein.

As discussed herein regarding polynucleotide assays of the invention, for example,
20 polynucleotides of the invention can be used as a hybridization probe for RNA, cDNA, or genomic DNA to isolate full length cDNAs or genomic clones encoding a polypeptide and to isolate cDNA or genomic clones of other genes that have a high sequence similarity to a polynucleotide set forth in the Sequence Listing. Such probes will generally comprise at least 15 bases. Preferably such probes will have at least 30 bases

and can have at least 50 bases. Particularly preferred probes will have between 30 bases and 50 bases, inclusive.

The region of each gene that comprises or is comprised by a polynucleotide sequence set forth in the Sequence Listing may be isolated by screening using a DNA
5 sequence provided in the Sequence Listing to synthesize an oligonucleotide probe. A labeled oligonucleotide having a sequence complementary to that of a polynucleotide of the invention is then used to screen a library of cDNA, genomic DNA or mRNA to identify members of the library which hybridize to the probe. For example, synthetic oligonucleotides are prepared which correspond to the desaturase promoter and intron
10 sequences. In particular, screening of cDNA libraries in phage vectors is useful in such methods due to lower levels of background hybridization.

Typically, a desaturase sequence obtainable from the use of nucleic acid probes will show 60-70% sequence identity between the target desaturase sequence and the encoding sequence used as a probe. However, lengthy sequences with as little as 50-60%
15 sequence identity may also be obtained. The nucleic acid probes may be a lengthy fragment of the nucleic acid sequence, or may also be a shorter, oligonucleotide probe. When longer nucleic acid fragments are employed as probes (greater than about 100 bp), one may screen at lower stringencies in order to obtain sequences from the target sample which have 20-50% deviation (i.e., 50-80% sequence homology) from the sequences used
20 as probe. Oligonucleotide probes can be considerably shorter than the entire nucleic acid sequence encoding an desaturase enzyme, but should be at least about 10, preferably at least about 15, and more preferably at least about 20 nucleotides. A higher degree of sequence identity is desired when shorter regions are used as opposed to longer regions. It may thus be desirable to identify regions of highly conserved amino acid sequence to
25 design oligonucleotide probes for detecting and recovering other related desaturase genes.

Shorter probes are often particularly useful for polymerase chain reactions (PCR), especially when highly conserved sequences can be identified. (See, Gould, *et al.*, *PNAS USA* (1989) 86:1934-1938.).

“Identity”, as is well understood in the art, is a relationship between two or more polypeptide sequences or two or more polynucleotide sequences, as determined by comparing the sequences. In the art, “identity” also means the degree of sequence relatedness between polypeptide or polynucleotide sequences, as determined by the match between strings of such sequences. “Identity” can be readily calculated by known methods including, but not limited to, those described in *Computational Molecular Biology*, Lesk, A.M., ed., Oxford University Press, New York (1988); *Biocomputing: Informatics and Genome Projects*, Smith, D.W., ed., Academic Press, New York, 1993; *Computer Analysis of Sequence Data, Part I*, Griffin, A.M. and Griffin, H.G., eds., Humana Press, New Jersey (1994); *Sequence Analysis in Molecular Biology*, von Heinje, G., Academic Press (1987); *Sequence Analysis Primer*, Gribskov, M. and Devereux, J., eds., Stockton Press, New York (1991); and Carillo, H., and Lipman, D., *SIAM J Applied Math*, 48:1073 (1988). Methods to determine identity are designed to give the largest match between the sequences tested. Moreover, methods to determine identity are codified in publicly available programs. Computer programs which can be used to determine identity between two sequences include, but are not limited to, GCG (Devereux, J., et al., *Nucleic Acids Research* 12(1):387 (1984); suite of five BLAST programs, three designed for nucleotide sequences queries (BLASTN, BLASTX, and TBLASTX) and two designed for protein sequence queries (BLASTP and TBLASTN) (Coulson, *Trends in Biotechnology*, 12: 76-80 (1994); Birren, *et al.*, *Genome Analysis*, 1: 543-559 (1997)). The BLAST X program is publicly available from NCBI and other sources (*BLAST Manual*, Altschul, S., *et al.*, NCBI NLM NIH, Bethesda, MD 20894;

Altschul, S., *et al.*, *J. Mol. Biol.*, 215:403-410 (1990)). The well known Smith Waterman algorithm can also be used to determine identity.

Parameters for polypeptide sequence comparison typically include the following:

Algorithm: Needleman and Wunsch, *J. Mol. Biol.* 48:443-453 (1970)

5 Comparison matrix: BLOSSUM62 from Hentikoff and Hentikoff, *Proc. Natl. Acad. Sci USA* 89:10915-10919 (1992)

Gap Penalty: 12

Gap Length Penalty: 4

A program which can be used with these parameters is publicly available as the
10 "gap" program from Genetics Computer Group, Madison Wisconsin. The above parameters along with no penalty for end gap are the default parameters for peptide comparisons.

Parameters for polynucleotide sequence comparison include the following:

Algorithm: Needleman and Wunsch, *J. Mol. Biol.* 48:443-453 (1970)

15 Comparison matrix: matches = +10; mismatches = 0

Gap Penalty: 50

Gap Length Penalty: 3

A program which can be used with these parameters is publicly available as the
"gap" program from Genetics Computer Group, Madison Wisconsin. The above
20 parameters are the default parameters for nucleic acid comparisons.

For immunological screening, antibodies to the protein can be prepared by injecting rabbits or mice with the purified protein or portion thereof, such methods of preparing antibodies being well known to those in the art. Either monoclonal or polyclonal antibodies can be produced, although typically polyclonal antibodies are more
25 useful for gene isolation. Western analysis may be conducted to determine that a related

protein is present in a crude extract of the desired plant species, as determined by cross-reaction with the antibodies to the encoded proteins. When cross-reactivity is observed, genes encoding the related proteins are isolated by screening expression libraries representing the desired plant species. Expression libraries can be constructed in a variety of commercially available vectors, including lambda gt11, as described in Sambrook, *et al. (Molecular Cloning: A Laboratory Manual, Second Edition (1989) Cold Spring Harbor Laboratory, Cold Spring Harbor, New York).*

Plant Constructs and Methods of Use

Of particular interest is the use of the polynucleotide sequences in recombinant DNA constructs to direct the transcription of the desaturase genomic sequences of the present invention in a host plant cell. The expression constructs generally comprise a promoter functional in a host plant cell operably linked to a nucleic acid sequence of the present invention and a transcriptional termination region functional in a host plant cell.

Those skilled in the art will recognize that there are a number of promoters which are functional in plant cells, and have been described in the literature. Chloroplast and plastid specific promoters, chloroplast or plastid functional promoters, and chloroplast or plastid operable promoters are also envisioned.

One set of promoters are constitutive promoters such as the CaMV35S or FMV35S promoters that yield high levels of expression in most plant organs. Enhanced or duplicated versions of the CaMV35S and FMV35S promoters are useful in the practice of this invention (Odell, *et al. (1985) Nature* 313:810-812; Rogers, U.S. Patent Number 5,378, 619). In addition, it may also be preferred to bring about expression of the sequences of the present invention in specific tissues of the plant, such as leaf, stem, root,

tuber, seed, fruit, etc., and the promoter chosen should have the desired tissue and developmental specificity.

Of particular interest is the expression of the nucleic acid sequences of the present invention from transcription initiation regions which are preferentially expressed in a plant seed tissue. Examples of such seed preferential transcription initiation sequences include those sequences derived from sequences encoding plant storage protein genes or from genes involved in fatty acid biosynthesis in oilseeds. Examples of such promoters include the 5' regulatory regions from such genes as napin (Kridlet *et al.*, *Seed Sci. Res.* 1:209:219 (1991)), phaseolin, zein, soybean trypsin inhibitor, ACP, stearyl-ACP desaturase, soybean α' subunit of β -conglycinin (soy 7s, (Chen *et al.*, *Proc. Natl. Acad. Sci.*, 83:8560-8564 (1986))) and oleosin.

It may be advantageous to direct the localization of proteins conferring desaturase to a particular subcellular compartment, for example, to the mitochondrion, endoplasmic reticulum, vacuoles, chloroplast or other plastidic compartment. For example, where the genes of interest of the present invention will be targeted to plastids, such as chloroplasts, for expression, the constructs will also employ the use of sequences to direct the gene to the plastid. Such sequences are referred to herein as chloroplast transit peptides (CTP) or plastid transit peptides (PTP). In this manner, where the gene of interest is not directly inserted into the plastid, the expression construct will additionally contain a gene encoding a transit peptide to direct the gene of interest to the plastid. The chloroplast transit peptides may be derived from the gene of interest, or may be derived from a heterologous sequence having a CTP. Such transit peptides are known in the art. See, for example, Von Heijne *et al.* (1991) *Plant Mol. Biol. Rep.* 9:104-126; Clark *et al.* (1989) *J. Biol. Chem.* 264:17544-17550; della-Cioppa *et al.* (1987) *Plant Physiol.* 84:965-968;

Romer *et al.* (1993) *Biochem. Biophys. Res Commun.* 196:1414-1421; and, Shah *et al.* (1986) *Science* 233:478-481.

Depending upon the intended use, the constructs may contain the entire genomic nucleic acid sequence or a particular non-coding region of such a sequence or a portion of such sequences. For example, where antisense inhibition of a given desaturase protein is desired, the entire sequence is not required. Furthermore, where desaturase sequences used in constructs are intended for use as probes, it may be advantageous to prepare constructs containing only a particular portion of a desaturase sequence, for example a sequence which encodes a highly conserved desaturase region.

The skilled artisan will recognize that there are various methods for the inhibition of expression of endogenous sequences in a host cell. Such methods include, but are not limited to, antisense suppression (Smith, *et al.* (1988) *Nature* 334:724-726), co-suppression (Napoli, *et al.* (1989) *Plant Cell* 2:279-289), ribozymes (PCT Publication WO 97/10328), combinations of sense and antisense (Waterhouse, *et al.* (1998) *Proc. Natl. Acad. Sci. USA* 95:13959-13964), promoter silencing (Park, *et al.* (1996) *Plant J.* 9(2):183-194), DNA binding proteins (Beerli, *et al.* (1997) *Proc. Natl. Acad. Sci. USA*, 95:14628-14633; and Liu, *et al.* (1998) *Proc. Natl. Acad. Sci. USA*, 94:5525-5530).

Methods for the suppression of endogenous sequences in a host cell typically employ the transcription or translation of at least a portion of the sequence to be suppressed. Such sequences may be homologous to coding as well as non-coding regions of the endogenous sequence.

Regulatory transcript termination regions may be provided in plant expression constructs of this invention as well. Transcript termination regions may be provided by the DNA sequence encoding the desaturase or a convenient transcription termination region derived from a different gene source, for example, the transcript termination region

which is naturally associated with the transcript initiation region. The skilled artisan will recognize that any convenient transcript termination region which is capable of terminating transcription in a plant cell may be employed in the constructs of the present invention.

5 Alternatively, constructs may be prepared to direct the expression of the desaturase sequences directly from the host plant cell plastid. Such constructs and methods are known in the art and are generally described, for example, in Svab, *et al.* (1990) *Proc. Natl. Acad. Sci. USA* 87:8526-8530 and Svab and Maliga (1993) *Proc. Natl. Acad. Sci. USA* 90:913-917 and in U.S. Patent Number 5,693,507.

10 A plant cell, tissue, organ, or plant into which the recombinant DNA constructs containing the expression constructs have been introduced is considered transformed, transfected, or transgenic. A transgenic or transformed cell or plant also includes progeny of the cell or plant and progeny produced from a breeding program employing such a transgenic plant as a parent in a cross and exhibiting an altered phenotype resulting from
15 the presence of a desaturase nucleic acid sequence.

 Plant expression or transcription constructs having a desaturase polynucleotide of the present invention as the DNA sequence of interest for increased or decreased expression thereof may be employed with a wide variety of plant life, particularly, plant life involved in the production of vegetable oils for edible and industrial uses. Most
20 especially preferred are temperate oilseed crops. Plants of interest include, but are not limited to, rapeseed (Canola and High Erucic Acid varieties), sunflower, safflower, cotton, soybean, peanut, coconut and oil palms, and corn. Depending on the method for introducing the recombinant constructs into the host cell, other DNA sequences may be required. Importantly, this invention is applicable to dicotyledons and monocotyledons

species alike and will be readily applicable to new and/or improved transformation and regulation techniques.

Of particular interest, is the use of plant desaturase promoter and/or intron constructs in plants to produce plants or plant parts, including, but not limited to leaves, stems, roots, reproductive, and seed, with a modified fatty acid composition. Of particular interest in the desaturase promoter and/or intron constructs is the use of the promoter and/or intron sequences of the Δ -12 and Δ -15 desaturase genomic sequences in sense or antisense orientations for the modification of fatty acid compositions in host cells.

The polynucleotides of the present invention can be used in the preparation of constructs for use in a variety of host cells. Host for use in the present invention include, but are not limited to plant cells, bacterial cells, fungal cells (including yeast), insect cells, and mammalian cells.

For example, to confirm the activity and specificity of the proteins encoded by the identified nucleic acid sequences as desaturase enzymes, *in vitro* assays can be performed in insect cell cultures using baculovirus expression systems. Such baculovirus expression systems are known in the art and are described by Lee, *et al.* U.S. Patent Number 5,348,886, the entirety of which is herein incorporated by reference.

The method of transformation in obtaining such transgenic plants is not critical to the instant invention, and various methods of plant transformation are currently available. Furthermore, as newer methods become available to transform crops, they may also be directly applied hereunder. For example, many plant species naturally susceptible to *Agrobacterium* infection may be successfully transformed via tripartite or binary vector methods of *Agrobacterium* mediated transformation. In many instances, it will be desirable to have the construct bordered on one or both sides by T-DNA, particularly

having the left and right borders, more particularly the right border. This is particularly useful when the construct uses *A. tumefaciens* or *A. rhizogenes* as a mode for transformation, although the T-DNA borders may find use with other modes of transformation. In addition, techniques of microinjection, DNA particle bombardment, and electroporation have been developed which allow for the transformation of various monocot and dicot plant species.

Normally, included with the DNA construct will be a structural gene having the necessary regulatory regions for expression in a host and providing for selection of transformant cells. The gene may provide for resistance to a cytotoxic agent, e.g. antibiotic, heavy metal, toxin, etc., complementation providing prototrophy to an auxotrophic host, viral immunity or the like. Depending upon the host species the expression construct or components thereof are introduced, one or more markers may be employed, where different conditions for selection are used for the different hosts.

Where *Agrobacterium* is used for plant cell transformation, a vector may be used which may be introduced into the *Agrobacterium* host for homologous recombination with T-DNA or the Ti- or Ri-plasmid present in the *Agrobacterium* host. The Ti- or Ri-plasmid containing the T-DNA for recombination may be armed (capable of causing gall formation) or disarmed (incapable of causing gall formation), the latter being permissible, so long as the *vir* genes are present in the transformed *Agrobacterium* host. The armed plasmid can give a mixture of normal plant cells and gall.

In some instances where *Agrobacterium* is used as the vehicle for transforming host plant cells, the expression or transcription construct bordered by the T-DNA border region(s) will be inserted into a broad host range vector capable of replication in *E. coli* and *Agrobacterium*, there being broad host range vectors described in the literature.

Commonly used is pRK2 or derivatives thereof. See, for example, Ditta, *et al.*, (*Proc.*

Nat. Acad. Sci., U.S.A. (1980) 77:7347-7351) and EPA 0 120 515, which are incorporated herein by reference. Alternatively, one may insert the sequences to be expressed in plant cells into a vector containing separate replication sequences, one of which stabilizes the vector in *E. coli*, and the other in *Agrobacterium*. See, for example, McBride and
5 Summerfelt (*Plant Mol. Biol.* (1990) 14:269-276), wherein the pRiHRI (Jouanin, *et al.*, *Mol. Gen. Genet.* (1985) 201:370-374) origin of replication is utilized and provides for added stability of the plant expression vectors in host *Agrobacterium* cells.

Included with the expression construct and the T-DNA will be one or more markers, which allow for selection of transformed *Agrobacterium* and transformed plant
10 cells. A number of markers have been developed for use with plant cells, such as resistance to chloramphenicol, kanamycin, the aminoglycoside G418, hygromycin, or the like. The particular marker employed is not essential to this invention, one or another marker being preferred depending on the particular host and the manner of construction.

15 For transformation of plant cells using *Agrobacterium*, explants may be combined and incubated with the transformed *Agrobacterium* for sufficient time for transformation, the bacteria killed, and the plant cells cultured in an appropriate selective medium. Once callus forms, shoot formation can be encouraged by employing the appropriate plant
hormones in accordance with known methods and the shoots transferred to rooting
20 medium for regeneration of plants. The plants may then be grown to seed and the seed used to establish repetitive generations and for isolation of vegetable oils.

For the alteration of unsaturated fatty acid production in a host cell, a second expression construct can be used in accordance with the present invention. For example, the desaturase expression construct can be introduced into a host cell in conjunction with

a second expression construct having a nucleotide sequence for a protein involved in fatty acid biosynthesis.

There are several possible ways to obtain the plant cells of this invention which contain multiple expression constructs. Any means for producing a plant comprising a construct having a DNA sequence encoding the expression construct of the present invention, and at least one other construct having another DNA sequence encoding an enzyme are encompassed by the present invention. For example, the expression construct can be used to transform a plant at the same time as the second construct either by inclusion of both expression constructs in a single transformation vector or by using separate vectors, each of which express desired genes. The second construct can be introduced into a plant which has already been transformed with the desaturase expression construct, or alternatively, transformed plants, one expressing the desaturase construct and one expressing the second construct, can be crossed to bring the constructs together in the same plant.

The invention now being generally described, it will be more readily understood by reference to the following examples which are included for purposes of illustration only and are not intended to limit the present invention.

EXAMPLES

Example 1 Cloning of Desaturase Genomic Sequences

1A. Soybean $\Delta 12$ Desaturase (*fad2-1*)

The soybean fad 2-1A sequence was identified by screening a soybean genomic library using a soybean fad2-1 cDNA probe. Three putative soy fad 2-1 clones were

identified and plaque purified. Two of the three soy fad 2-1 clones were ligated into pBluescript II KS+ (Stratagene) and sequenced. Both clones (14-1 and 11-12) were the same and matched the soy fad 2-1 cDNA exactly. The sequence of the entire fad2-1A clone is provided in SEQ ID NO: 1.

5 Prior to obtaining this full length clone, a portion of the fad2-1A genomic clone was PCR amplified using PCR primers designed from the 5' untranslated sequence (Primer 12506, 5'-ATACAA GCCACTAGGCAT-3', SEQ ID NO:9) and within the cDNA (Primer 11698: 5'-GATTGGCCATGCAATGAGGGAAAAGG-3', SEQ ID NO:10. The resulting PCR product, which contained the fad2-1A intron, was cloned into
10 the vector pCR 2.1 (Invitrogen) and sequenced. The soy fad 2-1A partial genomic clone (SEQ ID NO:27) and its intron region (SEQ ID NO:2) were identified by comparison to the soybean cDNA sequence using the Pustell comparison program in Macvector. The intron sequence begins after the ATG start codon, and is 420 bases long.

A second fad2-1 gene family member was also identified and cloned, and is
15 referred to herein as fad2-1B. The soy fad 2-1B partial genomic clone (SEQ ID NO:23) (contains the promoter (base pairs 1 - 1704); 5'UTR (base pairs 1705 - 1782); intron#1 (base pairs 1786 - 2190); and a portion of the fad2-1B coding region (base pairs 1783-1785 and 2191 - 2463)) and its intron region (SEQ ID NO:24) were identified by comparison to the soybean cDNA sequence using the Pustell comparison program in
20 Macvector. The intron sequence begins after the ATG start codon and is 405 bases long.

1B. Soybean $\Delta 15$ Desaturase (fad3)

The partial soybean fad 3 genomic sequence was PCR amplified from soybean DNA using primers 10632, 5'-

25 CUACUACUACUACTCGAGACAAAGCCTTTAGCCTATG-3' (SEQ ID NO:11), and

10633: 5'-CAUCAUCAUGGATCCCATGTC TCTCTATGCAAG-3' (SEQ ID NO:12). The Expand Long Template PCR system (Boehringer Mannheim) was used according to the manufacturers directions. The resulting PCR products were cloned into the vector pCR 2.1 (Invitrogen) and sequenced. The soy fad 3 partial genomic clone

5 sequence and the intron regions were confirmed by comparisons to the soybean fad 3 cDNA sequence using the Pustell program in Macvector. From the identified partial genomic soybean fad3 sequence (SEQ ID NO:3), seven introns were identified (SEQ ID NO:4 (intron #1), SEQ ID NO:5 (intron #2), SEQ ID NO:6 (intron #3A), SEQ ID NO:7 (intron #4), SEQ ID NO:8 (intron #5), SEQ ID NO:25 (intron #3B) and SEQ ID NO:26 (intron #3C)). Intron #1 is 192 base pairs long and is located between positions 294 and

10 485, intron #2 is 348 base pairs long and is located between positions 576 and 923, intron #3A is 142 base pairs long and is located between positions 991 and 1132, intron #3B is 98 base pairs long and is located between positions 1225 and 1322 , intron #3C is 115 base pairs long and is located between positions 1509 and 1623, intron #4 is 1231 base

15 pairs long and is located between positions 1705 and 2935, and intron #5 is 626 base pairs long and is located between positions 3074 and 3699.

Example 2 Expression constructs

20 The soybean fad2-1A intron sequence was amplified via PCR using the fad2-1A partial genomic clone (SEQ ID NO:27) as a template and primers 12701 (5'-ACGAATTCCTCGAGGTAAA TTAAATTGTGCCTGC-3' (SEQ ID NO:13)) and 12702 (5'-GCGAGATCTATCG ATCTGTGTCAAAGTATAAAC-3' (SEQ ID NO:14)). The resulting amplification products were cloned into the vector pCR 2.1 (Invitrogen) and

25 sequenced. The soyfad2-1A intron was then cloned into the expression cassette,

pCGN3892, in sense and antisense orientations. The vector pCGN3892 contains the soybean 7S promoter and a pea RBCS 3'. Both gene fusions were then separately ligated into pCGN9372, a vector that contains the CP4 gene regulated by the FMV promoter. The resulting expression constructs (PCGN5469 sense and pCGN5471
5 antisense) were used for transformation of soybean using biolistic methods described below.

The soybean fad2-1B intron sequence was amplified via PCR using the fad2-1B partial genomic clone (SEQ ID NO:23) as a template and primers 13883 (5'-
10 GCGATCGATGTATGATGCTAAATTAAATTGTGCCTG -3' (SEQ ID NO:30)) and 13876 (5'- GCGGAATTCCTGTGTCAAAGTATAAAGAAG -3' (SEQ ID NO:31)). The resulting amplification products were cloned into the vector pCR 2.1 (Invitrogen) and sequenced. The soyfad2-1B intron was fused to the 3' end of the soy fad 2-1A intron in plasmids pCGN5468 (contains the soybean 7S promoter fused to the soy fad2-1A intron
15 (sense) and a pea RBCS 3') or pCGN5470 (contains the soybean 7S promoter fused to the soy fad2-1A intron (antisense) and a pea RBCS 3') in sense or antisense orientation respectively. The resulting intron combo fusions were then ligated separately into pCGN9372, a vector that contains the CP4 gene regulated by the FMV promoter. The resulting expression constructs (pCGN5485, fad2-1A&B intron sense and pCGN5486,
20 fad2-1A&B intron antisense) were used for transformation of soybean using biolistic methods described below.

Four of the seven introns identified from the soybean fad 3 genomic clone were PCR amplified using the soy fad 3 partial genomic clone as template and primers as
25 follows: Intron #1, primers 12568: GATCGATGCCCGGGGTAATAATTTTGTGT

(SEQ ID NO:15) and 12569: CACGCCTCGAGTGTTCAATTCAATCAATG (SEQ ID NO:16); Intron #2, primers 12514: 5'-CACTCGAGTTAGTTCATACTGGCT (SEQ ID NO:17) and 12515: 5'-CGCATCGATTGCAAAATCCATCAAA (SEQ ID NO:18); Intron #4, primers 10926: 5'-

5 CUACUACUACUACTCGAGCGTAAATAGTGGGTGAACAC (SEQ ID NO:19) and 10927: 5'-CAUCAUCAUCAUCTCGAGGAATTCGTCCATTTTAGTACACC (SEQ ID NO:20) ; Intron #5, primers 10928: 5'-CUACUACUACUACTCGAGGCGCGT ACATTTTATTGCTTA (SEQ ID NO:21) and 10929: 5'-CAUCAUCAUCAUCT CGAGGAATTCTGCAGTGAATCCAAATG (SEQ ID NO:22). The resulting PCR
10 products for each intron were cloned into the vector pCR 2.1 (Invitrogen) and sequenced. Introns #1, #2, #4 and #5 were all ligated separately into the, pCGN3892, in sense or antisense orientations. pCGN3892 contains the soybean 7S promoter and a pea RBCS 3'. These fusions were ligated into pCGN9372, a vector that contains the CP4 gene regulated by the FMV promoter for transformation into soybean. The resulting expression
15 constructs (pCGN5455, fad3 intron#4 intron sense; pCGN5459, fad3 intron#4 intron antisense; pCGN5456, fad3 intron#5 intron sense; pCGN5460, fad3 intron#5 intron antisense; pCGN5466, fad3 intron#2 intron antisense; pCGN5473, fad3 intron#1 intron antisense;) were used for transformation of soybean using biolistic methods described below.

20 The soy fad3 Intron #3C and #4 were also PCR amplified from a second fad3 gene family member, herein referred to as fad3-1B. The soy fad3-1B introns #3C and #4 were PCR amplified from soybean DNA using the following primers, 5' CATGCTTTCTGTGCTTCTC 3' (SEQ ID NO:32) and , 5' GTTGATCCAACCATAGTCG 3' (SEQ ID NO:33). The PCR products were cloned into

the vector pCR 2.1 (Invitrogen) and sequenced. The sequences for the soy fad3-1B introns #3C and #4 are provided in SEQ ID NOs:28 and 29.

Example 3 Plant Transformation and Analysis

5 Linear DNA fragments containing the expression constructs for sense and antisense expression of the $\Delta 12$ and $\Delta 15$ desaturase introns were stably introduced into soybean (Asgrow variety A4922) by the method of McCabe, et.al. (1988) Bio/Technology 6:923-926. Transformed soybean plants were identified by selection on media containing glyphosate.

10 Fatty acid compositions were analyzed from seed of soybean lines transformed with the intron expression constructs using gas chromatography. T2 pooled seed and T2 single seed oil compositions demonstrate that the mono and polyunsaturated fatty acid compositions were altered in the oil of seeds from transgenic soybean lines as compared to that of the seed from non-transformed soybean. Table I provides a summary
15 of results which were obtained using the described constructs. These data clearly show that sense and antisense expression of the non-coding regions of the desaturase gene results in the modification of the fatty acid compositions. The data also shows that introns can be used to obtain a variety of lines with varying fatty acid compositions. Selections can be made from such lines depending on the desired relative fatty acid
20 composition. In addition, since each of the introns is able to modify the levels of each fatty acid to varying extents, it is contemplated that combinations of introns can be used depending on the desired compositions.

TABLE I

			Oleic	Linoleic	Linolenic
Fad 2					
wildtype (control)		5469-5 null T2 pool	18.15%	55.59%	7.97%
		10 seed average	13.89%	55.89%	9.067%
		5469-27 null T2 pool	19.15%	54.62%	9.32%
		A4922	15.75%	56.1%	8.75%
		5471-13 null T2 pool	17.02%	56.49%	9.08%
		10 seed average	13.86%	56.14%	9.49%
		A4922	14.95%	55.95%	9.07%
full length cDNA (control)	sense	5462-133 T2 pool	84%	2.17%	1.55%
		best 5462-133 T2 seed	84%	0.59%	1.76%
intron 1	sense	5469-6 T2 pool	29.93%	46.53%	
		5469-8 T2 pool	36.5%	42.11%	5.98%
		best 5469-6 T2 seed	44.41%	29.34%	6.68%
		best 5469-8 T2 seed	41.26%	33.16%	5.74%
		5469-14 T2 pool	61.06%	16.42%	7.75%
		5469-20 T2 pool	48.89%	31.61%	4.89%
		5469-22 T2 pool	80%	2.97%	4.78%
		best 5469-14 T2 seed	62.21%	11.97%	8.81%
		5485-3 T2 pool	63.54%	14.09%	7.32%
		5485-53 T2 pool	47.58%	27.64%	7.81%
	antisense	5471-8 T2 pool	31.05%	43.62%	7.07%
		5471-2 T2 pool	27.98%	48.88%	6.83%
		5471-26 T2 pool	32.66%	44.54%	6.76%
		best 5471-8 T2 seed	57.4%	23.37%	5.73%
		best 5471-2 T2 seed	28.08%	46.14%	6.52%
		best 5471-26 T2 seed	43.3%	34.15%	5.6%
		5486-33 T2 pool	32.37%	43.66%	6.87%
		5486-12 T2 pool	27.32%	46.97%	6.4%
		5486-40 T2 pool	26.79%	48.72%	6.55%
Fad 3					
wildtype (control)		5473-7 null T2 pool	15.65%	56.74%	9.55%
		A4922 T2 pool	19.84%	56.79%	7.48%
full length cDNA (control)	sense	5464-50 T2 pool	18.06%	62.03%	2.75%
		best 5464-50 T2 seed	17.08%	62.44%	1.72%
intron 1	antisense	5473-8 T2 pool	33.47%	45.97%	5.54%
		5473-1 T2 pool	33.34%	42.67%	7.59%
intron 2	antisense	5466-20 T2 pool	28.43%	48.83%	6.37%
		5466-16 T2 pool	27.61%	49.92%	5.96%
intron 4	sense	5455-19 T2 pool	40.35%	39.97%	4.61%
		5455-10 T2 pool	35.14%	43.59%	5.53%
		5455-57 T2 pool	38.04%	42.44%	5.24%
		5455-76 T2 pool	37.24%	42.42%	5.37%
		5455-107 T2 pool	36.44%	42.72%	5.62%
		best 5455-57 T2 seed	45.36%	35.55%	4.92%
		best 5455-76 T2 seed	35.3%	43.54%	5.53%
		best 5455-107 T2 seed	45.56%	34.85%	5.12%
	antisense	5459-2 T2 pool	34.5%	43.87%	5.59%
		5459-6 T2 pool	33.78%	44.12%	5.62%
		5459-20 T2 pool	28.26%	49.48%	5.5%
		best 5459-2 T2 seed	61.45%	23.45%	3.38%
		best 5459-6 T2 seed	53.51%	29.68%	3.53%

		best 5459-20 T2 seed	30%	50.55%	4.15%
intron 5	sense	5456-38 T2 pool	28.23%	49.59%	6.74%
		5456-62 T2 pool	28.94%	48.66%	6.25%
		best 5456-62 T2 seed	29.5%	43.69%	5.4%
	antisense	5460-9 T2 pool	29.78%	48.57%	5.54%
		5460-21 T2 pool	28.37%	49.79%	5.54%
		best 5460-21 T2 seed	35.18%	40.52%	5.33%

All publications and patent applications mentioned in this specification are indicative of the level of skill of those skilled in the art to which this invention pertains.

- 5 All publications and patent applications are herein incorporated by reference to the same extent as if each individual publication or patent application was specifically and individually indicated to be incorporated by reference.

- Although the foregoing invention has been described in some detail by way of illustration and example for purposes of clarity of understanding, it will be obvious that
- 10 certain changes and modifications may be practiced within the scope of the appended claims.

Claims

What is claimed is:

1. An isolated polynucleotide selected from the group consisting of:

a) a polynucleotide comprising SEQ ID NO: 1;

5 b) a polynucleotide sequence having at least 70% identity to that of SEQ ID NO: 1
over the entire length of SEQ ID NO: 1;

c) a polynucleotide sequence having at least 80% identity to that of SEQ ID NO: 1
over the entire length of SEQ ID NO: 1;

d) a polynucleotide sequence having at least 90% identity to that of SEQ ID NO: 1
10 over the entire length of SEQ ID NO: 1;

e) a polynucleotide sequence having at least 95% identity to that of SEQ ID NO: 1
over the entire length of SEQ ID NO: 1;

f) an polynucleotide sequence that hybridizes, under stringent conditions, to SEQ ID
NO: 1 or a fragment thereof; and

15 g) a polynucleotide sequence complementary to the polynucleotide sequence of (a),
(b), (c), (d), (e), or (f).

2. An isolated polynucleotide selected from the group consisting of:

a) a polynucleotide comprising SEQ ID NO: 2;

20 b) a polynucleotide sequence having at least 70% identity to that of SEQ ID NO: 2
over the entire length of SEQ ID NO: 2;

c) a polynucleotide sequence having at least 80% identity to that of SEQ ID NO: 2
over the entire length of SEQ ID NO: 2;

d) a polynucleotide sequence having at least 90% identity to that of SEQ ID NO: 2
25 over the entire length of SEQ ID NO: 2;

- e) a polynucleotide sequence having at least 95% identity to that of SEQ ID NO: 2
over the entire length of SEQ ID NO: 2;
- f) an polynucleotide sequence that hybridizes, under stringent conditions, to SEQ ID
NO: 2 or a fragment thereof; and
- 5 g) a polynucleotide sequence complementary to the polynucleotide sequence of (a),
(b), (c), (d), (e), or (f).

3. An isolated polynucleotide selected from the group consisting of:

- a) a polynucleotide comprising SEQ ID NO: 3;
- 10 b) a polynucleotide sequence having at least 70% identity to that of SEQ ID NO: 3
over the entire length of SEQ ID NO: 3;
- c) a polynucleotide sequence having at least 80% identity to that of SEQ ID NO: 3
over the entire length of SEQ ID NO: 3;
- d) a polynucleotide sequence having at least 90% identity to that of SEQ ID NO: 3
15 over the entire length of SEQ ID NO: 3;
- e) a polynucleotide sequence having at least 95% identity to that of SEQ ID NO: 3
over the entire length of SEQ ID NO: 3;
- f) an polynucleotide sequence that hybridizes, under stringent conditions, to SEQ ID
NO: 3 or a fragment thereof; and
- 20 g) a polynucleotide sequence complementary to the polynucleotide sequence of (a),
(b), (c), (d), (e), or (f).

4. An isolated polynucleotide selected from the group consisting of:

- a) a polynucleotide comprising SEQ ID NO: 4;

- b) a polynucleotide sequence having at least 70% identity to that of SEQ ID NO: 4
over the entire length of SEQ ID NO: 4;
- c) a polynucleotide sequence having at least 80% identity to that of SEQ ID NO: 4
over the entire length of SEQ ID NO: 4;
- 5 d) a polynucleotide sequence having at least 90% identity to that of SEQ ID NO: 4
over the entire length of SEQ ID NO: 4;
- e) a polynucleotide sequence having at least 95% identity to that of SEQ ID NO: 4
over the entire length of SEQ ID NO: 4;
- f) an polynucleotide sequence that hybridizes, under stringent conditions, to SEQ ID
10 NO: 4 or a fragment thereof; and
- g) a polynucleotide sequence complementary to the polynucleotide sequence of (a),
(b), (c), (d), (e), or (f).

5. An isolated polynucleotide selected from the group consisting of:

- 15 a) a polynucleotide comprising SEQ ID NO: 5;
- b) a polynucleotide sequence having at least 70% identity to that of SEQ ID NO: 5
over the entire length of SEQ ID NO: 5;
- c) a polynucleotide sequence having at least 80% identity to that of SEQ ID NO: 5
over the entire length of SEQ ID NO: 5;
- 20 d) a polynucleotide sequence having at least 90% identity to that of SEQ ID NO: 5
over the entire length of SEQ ID NO: 5;
- e) a polynucleotide sequence having at least 95% identity to that of SEQ ID NO: 5
over the entire length of SEQ ID NO: 5;
- f) an polynucleotide sequence that hybridizes, under stringent conditions, to SEQ ID
25 NO: 5 or a fragment thereof; and

- g) a polynucleotide sequence complementary to the polynucleotide sequence of (a), (b), (c), (d), (e), or (f).

6. An isolated polynucleotide selected from the group consisting of:

- 5 a) a polynucleotide comprising SEQ ID NO: 6;
- b) a polynucleotide sequence having at least 70% identity to that of SEQ ID NO: 6 over the entire length of SEQ ID NO: 6;
- c) a polynucleotide sequence having at least 80% identity to that of SEQ ID NO: 6 over the entire length of SEQ ID NO: 6;
- 10 d) a polynucleotide sequence having at least 90% identity to that of SEQ ID NO: 6 over the entire length of SEQ ID NO: 6;
- e) a polynucleotide sequence having at least 95% identity to that of SEQ ID NO: 6 over the entire length of SEQ ID NO: 6;
- f) an polynucleotide sequence that hybridizes, under stringent conditions, to SEQ ID
- 15 NO: 6 or a fragment thereof; and
- g) a polynucleotide sequence complementary to the polynucleotide sequence of (a), (b), (c), (d), (e), or (f).

7. An isolated polynucleotide selected from the group consisting of:

- 20 a) a polynucleotide comprising SEQ ID NO: 7;
- b) a polynucleotide sequence having at least 70% identity to that of SEQ ID NO: 7 over the entire length of SEQ ID NO: 7;
- c) a polynucleotide sequence having at least 80% identity to that of SEQ ID NO: 7 over the entire length of SEQ ID NO: 7;

- d) a polynucleotide sequence having at least 90% identity to that of SEQ ID NO: 7
over the entire length of SEQ ID NO: 7;
 - e) a polynucleotide sequence having at least 95% identity to that of SEQ ID NO: 7
over the entire length of SEQ ID NO: 7;
 - 5 f) an polynucleotide sequence that hybridizes, under stringent conditions, to SEQ ID
NO: 7 or a fragment thereof; and
 - g) a polynucleotide sequence complementary to the polynucleotide sequence of (a),
(b), (c), (d), (e), or (f).
- 10 8. An isolated polynucleotide selected from the group consisting of:
- a) a polynucleotide comprising SEQ ID NO: 8;
 - b) a polynucleotide sequence having at least 70% identity to that of SEQ ID NO: 8
over the entire length of SEQ ID NO: 8;
 - c) a polynucleotide sequence having at least 80% identity to that of SEQ ID NO: 8
15 over the entire length of SEQ ID NO: 8;
 - d) a polynucleotide sequence having at least 90% identity to that of SEQ ID NO: 8
over the entire length of SEQ ID NO: 8;
 - e) a polynucleotide sequence having at least 95% identity to that of SEQ ID NO: 8
over the entire length of SEQ ID NO: 8;
 - 20 f) an polynucleotide sequence that hybridizes, under stringent conditions, to SEQ ID
NO: 8 or a fragment thereof; and
 - g) a polynucleotide sequence complementary to the polynucleotide sequence of (a),
(b), (c), (d), (e), or (f).

9. An isolated polynucleotide selected from the group consisting of:

- a) a polynucleotide comprising SEQ ID NO: 23;
- b) a polynucleotide sequence having at least 70% identity to that of SEQ ID NO: 23 over the entire length of SEQ ID NO: 23;
- 5 c) a polynucleotide sequence having at least 80% identity to that of SEQ ID NO: 23 over the entire length of SEQ ID NO: 23;
- d) a polynucleotide sequence having at least 90% identity to that of SEQ ID NO: 23 over the entire length of SEQ ID NO: 23;
- e) a polynucleotide sequence having at least 95% identity to that of SEQ ID NO: 23 over the entire length of SEQ ID NO: 23;
- 10 f) an polynucleotide sequence that hybridizes, under stringent conditions, to SEQ ID NO: 23 or a fragment thereof; and
- g) a polynucleotide sequence complementary to the polynucleotide sequence of (a), (b), (c), (d), (e), or (f).

15 10. An isolated polynucleotide selected from the group consisting of:

- a) a polynucleotide comprising SEQ ID NO: 24;
- b) a polynucleotide sequence having at least 70% identity to that of SEQ ID NO: 24 over the entire length of SEQ ID NO: 24;
- 20 c) a polynucleotide sequence having at least 80% identity to that of SEQ ID NO: 24 over the entire length of SEQ ID NO: 24;
- d) a polynucleotide sequence having at least 90% identity to that of SEQ ID NO: 24 over the entire length of SEQ ID NO: 24;
- e) a polynucleotide sequence having at least 95% identity to that of SEQ ID NO: 24 over the entire length of SEQ ID NO: 24;
- 25

- f) an polynucleotide sequence that hybridizes, under stringent conditions, to SEQ ID NO: 24 or a fragment thereof; and
- g) a polynucleotide sequence complementary to the polynucleotide sequence of (a), (b), (c), (d), (e), or (f).

5

11. An isolated polynucleotide selected from the group consisting of:

- a) a polynucleotide comprising SEQ ID NO: 25;
- b) a polynucleotide sequence having at least 70% identity to that of SEQ ID NO: 25 over the entire length of SEQ ID NO: 25;
- 10 c) a polynucleotide sequence having at least 80% identity to that of SEQ ID NO: 25 over the entire length of SEQ ID NO: 25;
- d) a polynucleotide sequence having at least 90% identity to that of SEQ ID NO: 25 over the entire length of SEQ ID NO: 25;
- e) a polynucleotide sequence having at least 95% identity to that of SEQ ID NO: 25 over the entire length of SEQ ID NO: 25;
- 15 f) an polynucleotide sequence that hybridizes, under stringent conditions, to SEQ ID NO: 25 or a fragment thereof; and
- a polynucleotide sequence complementary to the polynucleotide sequence of (a), (b), (c), (d), (e), or (f).

20

12. An isolated polynucleotide selected from the group consisting of:

- a) a polynucleotide comprising SEQ ID NO: 26;
- b) a polynucleotide sequence having at least 70% identity to that of SEQ ID NO: 26 over the entire length of SEQ ID NO: 26;

- c) a polynucleotide sequence having at least 80% identity to that of SEQ ID NO: 26
over the entire length of SEQ ID NO: 26;
- d) a polynucleotide sequence having at least 90% identity to that of SEQ ID NO: 26
over the entire length of SEQ ID NO: 26;
- 5 e) a polynucleotide sequence having at least 95% identity to that of SEQ ID NO: 26
over the entire length of SEQ ID NO: 26;
- f) an polynucleotide sequence that hybridizes, under stringent conditions, to SEQ ID
NO: 26 or a fragment thereof; and
a polynucleotide sequence complementary to the polynucleotide sequence of (a),
10 (b), (c), (d), (e), or (f).

13. An isolated polynucleotide selected from the group consisting of:

- a) a polynucleotide comprising SEQ ID NO: 27;
- b) a polynucleotide sequence having at least 70% identity to that of SEQ ID NO: 27
15 over the entire length of SEQ ID NO: 27;
- c) a polynucleotide sequence having at least 80% identity to that of SEQ ID NO: 27
over the entire length of SEQ ID NO: 27;
- d) a polynucleotide sequence having at least 90% identity to that of SEQ ID NO: 27
over the entire length of SEQ ID NO: 27;
- 20 e) a polynucleotide sequence having at least 95% identity to that of SEQ ID NO: 27
over the entire length of SEQ ID NO: 27;
- f) an polynucleotide sequence that hybridizes, under stringent conditions, to SEQ ID
NO: 27 or a fragment thereof; and
a polynucleotide sequence complementary to the polynucleotide sequence of (a),
25 (b), (c), (d), (e), or (f).

14. An isolated polynucleotide selected from the group consisting of:

- a) a polynucleotide comprising SEQ ID NO: 28;
- b) a polynucleotide sequence having at least 70% identity to that of SEQ ID NO: 28
5 over the entire length of SEQ ID NO: 28;
- c) a polynucleotide sequence having at least 80% identity to that of SEQ ID NO: 28
over the entire length of SEQ ID NO: 28;
- d) a polynucleotide sequence having at least 90% identity to that of SEQ ID NO: 28
over the entire length of SEQ ID NO: 28;
- 10 e) a polynucleotide sequence having at least 95% identity to that of SEQ ID NO: 28
over the entire length of SEQ ID NO: 28;
- f) an polynucleotide sequence that hybridizes, under stringent conditions, to SEQ ID
NO: 28 or a fragment thereof; and
a polynucleotide sequence complementary to the polynucleotide sequence of (a),
15 (b), (c), (d), (e), or (f).

15. An isolated polynucleotide selected from the group consisting of:

- a) a polynucleotide comprising SEQ ID NO: 29;
- b) a polynucleotide sequence having at least 70% identity to that of SEQ ID NO: 29
20 over the entire length of SEQ ID NO: 29;
- c) a polynucleotide sequence having at least 80% identity to that of SEQ ID NO: 29
over the entire length of SEQ ID NO: 29;
- d) a polynucleotide sequence having at least 90% identity to that of SEQ ID NO: 29
over the entire length of SEQ ID NO: 29;

e) a polynucleotide sequence having at least 95% identity to that of SEQ ID NO: 29 over the entire length of SEQ ID NO: 29;

f) an polynucleotide sequence that hybridizes, under stringent conditions, to SEQ ID NO: 29 or a fragment thereof; and

5 a polynucleotide sequence complementary to the polynucleotide sequence of (a), (b), (c), (d), (e), or (f).

16. An intron obtained from a genomic polynucleotide sequence selected from the group consisting of:

10 a) a genomic polynucleotide sequence having at least 70% identity to coding regions of SEQ ID NO: 1 over the entire coding regions of SEQ ID NO:1;

b) a genomic polynucleotide sequence having at least 80% identity to coding regions of SEQ ID NO: 1 over the entire coding regions of SEQ ID NO:1;

15 c) a genomic polynucleotide sequence having at least 90% identity to coding regions of SEQ ID NO: 1 over the entire coding regions of SEQ ID NO:1; and

d) a genomic polynucleotide sequence having at least 95% identity to coding regions of SEQ ID NO: 1 over the entire coding regions of SEQ ID NO:1.

20 17. An intron obtained from a genomic polynucleotide sequence selected from the group consisting of:

a) a genomic polynucleotide sequence having at least 70% identity to coding regions of SEQ ID NO: 3 over the entire coding regions of SEQ ID NO:3;

b) a genomic polynucleotide sequence having at least 80% identity to coding regions of SEQ ID NO: 3 over the entire coding regions of SEQ ID NO:3;

c) a genomic polynucleotide sequence having at least 90% identity to coding regions of SEQ ID NO: 3 over the entire coding regions of SEQ ID NO:3; and

d) a genomic polynucleotide sequence having at least 95% identity to coding regions of SEQ ID NO: 3 over the entire coding regions of SEQ ID NO:3.

5

18. An intron obtained from a genomic polynucleotide sequence selected from the group consisting of:

a) a genomic polynucleotide sequence having at least 70% identity to coding regions of SEQ ID NO:23 over the entire coding regions of SEQ ID NO:23;

10 b) a genomic polynucleotide sequence having at least 80% identity to coding regions of SEQ ID NO:23 over the entire coding regions of SEQ ID NO:23;

c) a genomic polynucleotide sequence having at least 90% identity to coding regions of SEQ ID NO:23 over the entire coding regions of SEQ ID NO:23; and

15 d) a genomic polynucleotide sequence having at least 95% identity to coding regions of SEQ ID NO:23 over the entire coding regions of SEQ ID NO:23.

19. An intron obtained from a genomic polynucleotide sequence selected from the group consisting of:

20 a) a genomic polynucleotide sequence having at least 70% identity to coding regions of SEQ ID NO:27 over the entire coding regions of SEQ ID NO:27;

b) a genomic polynucleotide sequence having at least 80% identity to coding regions of SEQ ID NO:27 over the entire coding regions of SEQ ID NO:27;

c) a genomic polynucleotide sequence having at least 90% identity to coding regions of SEQ ID NO:27 over the entire coding regions of SEQ ID NO:27; and

d) a genomic polynucleotide sequence having at least 95% identity to coding regions of SEQ ID NO:27 over the entire coding regions of SEQ ID NO:27.

20. A recombinant DNA construct comprising at least one of the polynucleotide sequences of Claims 1-19.

21. The recombinant DNA construct according to Claim 20, wherein said polynucleotide sequence is an intron sequence.

22. The recombinant DNA construct according to Claim 21, wherein said intron sequence is in an orientation selected from the group consisting of sense and antisense.

23. A plant cell comprising the DNA construct of 20.

24. A plant comprising the cell of Claim 24.

25. A method of modifying the fatty acid composition in a plant cell, said method comprising:

transforming a plant cell with the construct of Claim 21 and, growing said cell under conditions wherein transcription of said polynucleotide sequence is initiated,

whereby said fatty acid composition of said cell is modified.

26. The method according to Claim 25, wherein said modification is selected from the group consisting of an increase in oleic acid, a decrease in linolenic acid and a decrease in linoleic acid.

5 27. The method according to Claim 25, wherein said polynucleotide sequence is an intron sequence.

28. The method according to Claim 27, wherein said intron sequence is in an orientation selected from the group consisting of sense and antisense.

10

29. A plant cell produced by the method of claim 25.

30. A method of inhibiting gene expression in a plant cell, comprising the steps of:
transforming a plant cell with a DNA construct comprising a non-coding region of a gene to
15 be inhibited positioned in a sense orientation; and
growing said cell under conditions wherein transcription of said non-coding region is initiated, whereby said expression of said gene is inhibited.

31. The method according to claim 30 wherein said non-coding region is selected from
20 the group consisting of an intron, a promoter region, a 5' untranslated region and portions of such sequences.

32. The method according to claim 30 wherein said non-coding region is selected from the group consisting of SEQ ID NO:2, SEQ ID NO:24, SEQ ID NO:4, SEQ ID NO:5, SEQ ID

NO:6, SEQ ID NO:7, SEQ ID NO:8, SEQ ID NO:25, SEQ ID NO:26, SEQ ID NO:28 and SEQ ID NO:29.

33. The method according to claim 30 wherein said gene encodes desaturase.

5

34. A method of inhibiting desaturase expression in a plant cell, comprising the steps of:
transforming a plant cell with a DNA construct comprising a non-coding region of a gene
encoding desaturase positioned in an antisense orientation; and
growing said cell under conditions wherein transcription of said non-coding region is
initiated, whereby said expression of said desaturase is inhibited.

10

35. The method according to claim 34 wherein said non-coding region is selected from
the group consisting of an intron, a promoter region, a 5' untranslated region and portions of such
sequences.

15

36. The method according to claim 34 wherein said non-coding region is selected from
the group consisting of SEQ ID NO:2, SEQ ID NO:24, SEQ ID NO:4, SEQ ID NO:5, SEQ ID
NO:6, SEQ ID NO:7, SEQ ID NO:8, SEQ ID NO:25, SEQ ID NO:26, SEQ ID NO:28 and SEQ ID
NO:29.

20

37. A plant cell produced according to the method of claim 34.

38. The plant cell according to claim 37 wherein said cell includes an oil composition
comprising at least about 80 - 85% oleic acid, no more than about 1 - 2% linoleic acid and no more
than about 1-3% linolenic acid.

25

39. The plant cell according to claim 37 wherein said cell includes an oil composition comprising at least about 50 - 75% oleic acid, no more than about 10 - 30% linoleic acid and no more than about 1-3% linolenic acid.

5

40. A method of modifying fatty acid composition in a plant cell, comprising the steps of:

transforming a plant cell with a DNA construct comprising a non-coding region of a gene encoding desaturase positioned in a sense or an antisense orientation; and

10 growing said cell under conditions wherein transcription of said non-coding region is initiated, whereby said expression of said desaturase is inhibited.

41. The method according to claim 40 wherein said non-coding region is selected from the group consisting of an intron, a promoter region, a 5' untranslated region and portions of such
15 sequences.

42. The method according to claim 41 wherein said non-coding region is selected from the group consisting of SEQ ID NO:2, SEQ ID NO:24, SEQ ID NO:4, SEQ ID NO:5, SEQ ID NO:6, SEQ ID NO:7, SEQ ID NO:8, SEQ ID NO:25, SEQ ID NO:26, SEQ ID NO:28 and SEQ ID
20 NO:29.

43. A plant cell produced according to the method of claim 40.

44. The plant cell according to claim 43 wherein said cell includes an oil composition comprising at least about 80 - 85% oleic acid, no more than about 1 - 2% linoleic acid and no more than about 1-3% linolenic acid.

5 45. The plant cell according to claim 43 wherein said cell includes an oil composition comprising at least about 50 - 75% oleic acid, no more than about 10 - 30% linoleic acid and no more than about 1-3% linolenic acid.

10 46. A method of inhibiting desaturase expression in a plant cell, comprising the steps of:
transforming a plant cell with a DNA construct comprising a nucleic acid sequence capable of binding to or cleaving a non-coding region of a gene encoding desaturase; and
growing said cell under conditions wherein transcription of said nucleic acid sequence is initiated, whereby said expression of said desaturase is inhibited.

15 47. A plant cell produced according to the method of claim 46.

48. A oil seed composition comprising:
at least about 50 - 75% oleic acid, no more than about 10 - 30% linoleic acid and no more than about 1-3% linolenic acid.

20

SEQUENCE LISTING

<110> Fillatti, Joanne J.

<120> Nucleic Acid Sequences and Methods of
Use for the Production of Plants with Modified
Polyunsaturated Fatty Acids

<130> 17138/00/WO

<140> new application

<141> 2000-08-11

<150> 60/151,224

<151> 1999-08-26

<150> 60/172,128

<151> 1999-12-17

<160> 33

<170> FastSEQ for Windows Version 4.0

<210> 1

<211> 4497

<212> DNA

<213> Glycine max

<400> 1

cttgcttggt	aacaacgtcg	tcaagttatt	atthttgttct	tttttttttt	atcatatttc	60
ttatthttggt	ccaagtatgt	catatthttga	tccatcttga	caagtagatt	gtcatgtagg	120
aataggaata	tcactttaaa	ttttaaagca	ttgattagtc	tgtaggcaat	attgtcttct	180
tcttctctct	tattaatatt	ttttattctg	ccttcaatca	ccagttatgg	gagatggatg	240
taataactaaa	taccatagtt	gttctgcttg	aagtttagtt	gtatagttgt	tctgcttgaa	300
gttttagttgt	gtgtaatggt	tcagcgttgg	cttccccctg	aactgctaca	atggtagtga	360
atatatatth	tttgcatgtg	tcattthttt	cttttactta	atcttcattg	ctttgaaatt	420
aataaaacaa	aaagaaggac	cgaatagttt	gaagtttgaa	ctattgccta	ttcatgtaac	480
ttattcaccc	aatcttatat	agttthttctg	gtagagatca	ttttaaattg	aaggatataa	540
attaagagga	aatacttgta	tgtgatgtgt	ggcaatttgg	aagatcatgc	gtagagagtt	600
taatggcagg	ttttgcaaatt	tgacctgtag	tcataattac	actggggccct	ctcggagttt	660
tgtgccttht	tgttgctcgt	gtgtttgggt	ctgcatgtta	gcctcacaca	gatatttagt	720
agttgttggt	ctgcatataa	gcctcacacg	tatactaaac	gagtgaacct	caaaatcatg	780
gccttacacc	tattgagtga	aattaatgaa	cagtgcattg	gagtatgtga	ctgtgacaca	840
acccccgggt	ttcatattgc	aatgtgctac	tgtgggtgatt	aaccttgcta	cactgtcgtc	900
cttgthttgt	tccttatgta	tattgatacc	ataaattatt	actagtatat	cattttatat	960
tgtccatacc	attacgtgtt	tatagtctct	ttatgacatg	taattgaatt	ttttaattat	1020
aaaaaataat	aaaacttaat	tacgtactat	aaagagatgc	tcttgactag	aattgtgatc	1080
tcctagthtt	ctaaccatat	actaatattt	gcttgatttg	atagccccctc	cgthcccaag	1140
agtataaaac	tgcatcgaat	aatacaagcc	actaggcatg	gtaaattaaa	ttgtgcctgc	1200
acctcgggat	atthtcatgtg	gggttcattca	tatttgthtga	ggaaaagaaa	ctccccgaaat	1260
tgaattatgc	atthtatatat	cctthtttcat	ttctagattt	cctgaaggct	taggtgtagg	1320
cacctagcta	gtagctacaa	tatcagcact	tctctctatt	gataaacaat	tggctgtaat	1380
gccgcagtag	aggacgatca	caacatttht	tgctggttac	ttthttgttht	atgggtcatga	1440
tttcaactctc	tctaattctct	ccatttcattt	tgtagthtgc	attatcttht	gattthttcac	1500

tacctgggtt	aaaattgagg	gattgtagtt	ctgttggtac	atattacaca	ttcagcaaaa	1560
caactgaaac	tcaactgaac	ttgtttatac	tttgacacag	ggtctagcaa	aggaaacaac	1620
aatgggaggt	agaggtcgtg	tggcaaaagt	gaagttcaag	ggaagaagcc	tctctcaagg	1680
gttccaaaca	caaagccacc	attcactggt	ggccaactca	agaaagcaat	tccaccacac	1740
tgttttcagc	gctccctcct	cacttcattc	tcctatgttg	tttatgacct	ttcatttgcc	1800
ttcattttct	acattgccac	cacctacttc	cacctccttc	ctcaaccctt	ttccctcatt	1860
gcatggccaa	tctattgggt	tctccaaggt	tgccttctca	ctgggtgtgtg	ggtgattgct	1920
cacgagtgtg	gtcaccatgc	cttcagcaag	taccaatggg	ttgatgatgt	tgtgggtttg	1980
acccttcaat	caacactttt	agtcccttat	ttctcatgga	aaataagcca	tcgccgccat	2040
cactccaaca	cagggtccct	tgaccgtgat	gaagtgtttg	tcccaaaacc	aaaatccaaa	2100
gttgcatggg	tttccaagta	cttaaacac	cctctaggaa	gggctgtttc	tcttctcgtc	2160
acactcaca	taggggtggcc	tatgtattta	gccttcaatg	tctctggtag	accctatgat	2220
agttttgcaa	gccactacca	cccttatgct	cccatatatt	ctaaccgtga	gaggcttctg	2280
atctatgtct	ctgatgttgc	tttgttttct	gtgacttact	ctctctaccg	tgttgcaacc	2340
ctgaaagggg	tgggtttggc	gctatgtgtt	tatgggggtg	ccttgctcat	tgtgaacggg	2400
tttcttgtga	ctatcacata	tttgcagcac	acacactttg	ccttgccctca	ttacgattca	2460
tcagaatggg	actggctgaa	gggagctttg	gcaactatgg	acagagatta	tgggattctg	2520
aacaaggtgt	ttcatcacat	aactgatact	catgtggctc	accatctctt	ctctacaatg	2580
ccacattacc	atgcaatgga	ggcaaccaat	gcaatcaagc	caatattggg	tgagtactac	2640
caatttgatg	acacaccatt	ttacaaggca	ctgtggagag	aagcgagaga	gtgcctctat	2700
gtggagccac	atgaaggaa	atccgagaag	ggcgtgtatt	ggtacaggaa	caagtattga	2760
tggagcaacc	aatgggccat	agtgggagtt	atgggaagtt	tgtcatgtat	tagtacataa	2820
ttagtagaat	gttataaata	agtggatttg	ccgcgtaatg	actttgtgtg	tattgtgaaa	2880
cagcttgttg	cgatcatggg	tataatgtaa	aaataattct	ggtattaatt	acatgtggaa	2940
agtgttctgc	ttatagcttt	ctgcctaaaa	tgcacgctgc	acgggacaat	atcattggta	3000
atttttttaa	aatctgaatt	gaggctactc	ataatactat	ccataggaca	tcaaagacat	3060
gttgcattga	ctttaagcag	aggttcatct	agaggattac	tgcataggct	tgaactacaa	3120
gtaatttaag	ggacgagagc	aacttttagct	ctaccacgtc	gtttttacaag	gttattaaaa	3180
tcaaattgat	cttattaaaa	ctgaaaattt	gtaataaaat	gctattgaaa	aattaaaaata	3240
tagcaaacac	ctaaattgga	ctgattttta	gattcaaatt	taataattaa	tctaaattaa	3300
acttaaat	tataatatat	gtcttgtaat	atatcaagtt	ttttttttta	ttattgagtt	3360
tggaaacata	taataaggaa	cattagttaa	tattgataat	ccactaagat	cgacttagta	3420
ttacagtatt	tggatgattt	gtatgagata	ttcaaacttc	actcttatca	taatagagac	3480
aaaagttaat	actgatgggtg	gagaaaaaaa	aatgttattg	ggagcatatg	gtaagataag	3540
acggataaaa	atatgctgca	gcctggagag	ctaattgtatt	ttttgggtgaa	gttttcaagt	3600
gacaactatt	catgatgaga	acacaataat	attttctact	tacctatccc	acataaaaata	3660
ctgattttta	taatgatgat	aaataatgat	taaaatat	gattccttgt	taagagaaat	3720
aaggaaaaaca	taaatattct	catggaaaaa	tcagcttgta	ggagtagaaa	ctttctgatt	3780
ataattttta	tcaagtttta	ttcattcttt	taatttttatt	attagtacaa	aatcattctc	3840
ttgaatttag	agatgtatgt	tgtagcttaa	tagtaatttt	ttattttttat	aataaaaattc	3900
aagcagtcaa	atttcatcca	aataatcgtg	ttcgtgggtg	taagtcagtt	attccttctt	3960
atcttaatat	acacgcaaag	gaaaaaataa	aaataaaatt	cgaggaagcg	cagcagcagc	4020
tgataccacg	ttgggtgacg	aaactgataa	aaagcgctgt	cattgtgtct	ttgtttgatc	4080
atcttcacaa	tcacatctcc	agaacacaaa	gaagagtgac	ccttcttctt	gttattccac	4140
ttgcgttagg	tttctacttt	cttctctctc	tctctctctc	tcttcatctc	tcattttttcc	4200
ctcaaacat	caatcaattt	tcattcagat	tcgtaaaatt	ctcgattaga	tcacgggggt	4260
aggtctccca	ctttatcttt	tccaagcct	ttctctttcc	ccctttccct	gtctgcccc	4320
taaaattcag	gatcggaaac	gaactgggtt	cttgaatttc	actctagatt	ttgacaaatt	4380
cgaagtgtgc	atgcactgat	gcgaccact	cccccttttt	tgcattaaac	aattatgaat	4440
tgagggtttt	cttgcgatca	tcattgcttg	aattgaatca	tattaggttt	agattct	4497

<210> 2

<211> 420

<212> DNA

<213> Glycine max

<400> 2

gtaaattaaa	ttgtgcctgc	acctcgggat	atttcattgtg	gggttcatca	tattttgttga	60
ggaaaagaaa	ctcccgaat	tgaattatgc	atttatatat	cctttttcat	ttctagattt	120
cctgaaggct	taggtgtagg	cacctagcta	gtagctacaa	tatcagcact	tctctctatt	180
gataaacaat	tggctgtaat	gccgcagtag	aggacgatca	caacatttcg	tgctggttac	240
tttttgtttt	atggctcatga	tttcaactc	tctaactctc	ccattcattt	tgtagtgtgc	300
attatcttta	gattttttcac	tacctgggtt	aaaattgagg	gattgtagt	ctgttggtag	360
atattacaca	ttcagcaaaa	caactgaaac	tcaactgaac	ttgtttatac	tttgacacag	420

<210> 3

<211> 4010

<212> DNA

<213> Glycine max

<400> 3

acaaagcctt	tagcctatgc	tgccaataat	ggataccaac	aaaagggttc	ttcttttggat	60
tttgatccta	gcgctcctcc	accgtttaag	attgcagaaa	tcagagcttc	aataccaaaa	120
cattgctggg	tcaagaatcc	atggagatcc	ctcagttatg	ttctcaggga	tgtgcttgta	180
attgctgcat	tgggtggctgc	agcaattcac	ttcgacaact	ggcttctctg	gctaactctat	240
tgccccattc	aaggcacaat	gttctgggct	ctctttgttc	ttggacatga	ttggtaataa	300
tttttgtgtt	tcttactctt	tttttttttt	ttttgtttat	gatatgaatc	tcacacattg	360
ttctgttatg	tcatttcttc	ttcatttggc	tttagacaac	ttaaatttga	gatctttatt	420
atgtttttgc	ttatatggta	aagtgattct	tcattatttc	attcttcatt	gattgaattg	480
aacagtggcc	atggaagctt	ttcagatagc	cctttgctga	atagcctggg	gggacacatc	540
ttgcattcct	caattcttgt	gccataccat	ggatgggttag	ttcatactgg	cttttttggg	600
tgttcatttg	tcattgaaaa	aaaatctttt	gttgattcaa	ttatttttat	agtgtgtttg	660
gaagcccggt	tgagaaaaa	agaaatcgca	tctggaatgt	gaaagttata	actattttagc	720
ttcatctgtc	gttgcaagtt	cttttattgg	ttaaattttt	atagcgtgct	aggaaaccca	780
ttcgagaaaa	taagaaatca	catctggaat	gtgaaagtta	taactgttag	cttctgagta	840
aacgtggaaa	aaccacattt	tggatttggg	accaaatttt	atttgataaa	tgacaaccaa	900
attgatattg	atggattttg	caggagaatt	agccacagaa	ctcaccatga	aaaccatgga	960
cacattgaga	aggatgagtc	atgggttcca	gtatgtgatt	aattgcttct	cctatagtgt	1020
ttcttgattc	aattacattt	tatttatttg	gtagggtccaa	gaaaaaagg	aatctttatg	1080
cttcttgagg	ctgttcttga	acatggctct	tttttatgtg	tcattatctt	agttaacaga	1140
gaagattttc	aagaatctag	acagcatgac	aagactcatt	agattcactg	tgccattttc	1200
atgtttgtgt	atccaattta	tttgggtgag	gatttttttga	cttgggaagac	aacaacacat	1260
tattattata	atatggttca	aaacaatgac	tttttcttta	tgatgtgaac	tccatttttt	1320
agttttcaag	aagccccgga	aagggaaggct	ctcacttcaa	tccctacagc	aatctgtttc	1380
caccagtgga	gagaaaagga	atagcaatat	caacactgtg	ttgggctacc	atgttttctc	1440
tgcttatcta	tctctcattc	attaactagt	ccacttctag	tgctcaagct	ctatggaatt	1500
ccatattggg	taactaaatt	actcctacat	tgttactttt	tcctcctttt	ttttattatt	1560
tcaattctcc	aattggaaat	ttgaaatagt	taccataatt	atgtaattgt	ttgatcatgt	1620
gcagatgttt	gttatgtggc	tggactttgt	cacatacttg	catcaccatg	gtcaccacca	1680
gaaactgcct	tggtagcgcg	gcaaggtaac	aaaaataaat	agaaaatagt	gggtgaacac	1740
ttaaatgcga	gatagtaata	cctaaaaaaa	gaaaaaaata	taggtataat	aaataatata	1800
actttcaaaa	taaaaagaaa	tcataagatc	tagcgtagtg	tttggagtga	aatgatgttc	1860
acctaccatt	actcaaagat	tttgttgtgt	cccttagttc	attcttatta	ttttacatat	1920
cttacttgaa	aagacttttt	aattattcat	tgagatctta	aagtgactgt	ttaaattaaaa	1980
taaaaaacaa	gtttgtttaa	acttcaaata	aataagagtg	aagggtgtgt	catttgtctt	2040
ctttctttta	ttgcgttatt	aatcacgttt	ctcttctctt	tttttttttt	cttctctgct	2100
ttccacccat	tatcaagttc	atgtgaagca	gtggcggatc	tatgtaaaatg	agtggggggc	2160
aattgcaccc	acaagatttt	attttttatt	tgtacaggaa	taataaaaata	aaacttttgc	2220
cccataaaaa	ataaatattt	tttcttaaaa	taatgcaaaa	taaatataag	aaataaaaaag	2280
agaataaatt	attatttaatt	ttattatttt	gtactttttt	tttagttttt	tttagcggtta	2340

gatttttttt	tcatgacatt	atgtaatctt	ttaaaagcat	gtaatatatt	tattttgtga	2400
aaataaatat	aatgatcat	attagtctca	gaatgtataa	actaataata	attttatcac	2460
taaaagaaat	tctaatttag	tccataaata	agtaaaacaa	gtgacaatta	tattttatat	2520
ttacttaatg	tgaaataata	cttgaacatt	ataataaaac	ttaatgacag	gagatattac	2580
atagtgccat	aaagatatatt	taaaaaataa	aatcattaat	acactgtact	actatataat	2640
attcgatata	tatttttaac	atgattctca	atagaaaaat	tgtattgatt	atattttatt	2700
agacatgaat	ttacaagccc	cgtttttcat	ttatagctct	tacctgtgat	ctattgtttt	2760
gcttcgctgt	ttttgttggg	caagggactt	agatgtcaca	atattaatac	tagaagtaaa	2820
tatttatgaa	aacatgtacc	ttacctcaac	aaagaaagtg	tggttaagtgg	caacacacgt	2880
gttgcatttt	tggtccagca	ataacacgtg	tttttgtggg	gtactaaaat	ggacaggaat	2940
ggagtatttt	aagaggtggc	ctcaccactg	tggatcgtga	ctatgggtgg	atcaataaca	3000
ttcaccatga	cattggcacc	catgttatcc	accatctttt	cccccaaatt	cctcattatc	3060
acctcgttga	agcggtagat	tttattgctt	attcacctaa	aaacaataca	attagtacat	3120
ttgttttatc	tcttggaagt	tagtcatttt	cagttgcatg	attctaatac	tctctccatt	3180
cttaaatcat	gttttcacac	ccacttcatt	taaaataaga	acgtgggtgt	tatttttaatt	3240
tctattcact	aacatgagaa	attaacttat	ttcaagtaat	aatttttaaaa	tatttttatg	3300
ctattatttt	attacaaata	attatgtata	ttaagtttat	tgattttata	ataattatat	3360
taaaattata	tcgatattaa	tttttgattc	actgatagtg	ttttatattg	ttagtactgt	3420
gcatttattt	taaaattggc	ataaataata	tatgtaacca	gctcactata	ctatactggg	3480
agcttgggtg	tgaaaggggt	tcccaaccct	cctttctagg	tgtacatgct	ttgatacttc	3540
tggtaccttc	ttatatcaat	ataaattata	ttttgctgat	aaaaaaacat	ggttaaccat	3600
taaattcttt	ttttaaaaaa	aaaactgtat	ctaaactttg	tattattaaa	aagaagtctg	3660
agattaacaa	taaactaaca	ctcatttgga	ttcactgcag	acacaagcag	caaaaccagt	3720
tcttgagat	tactaccgtg	agccagaaag	atctgcgcca	ttaccatttc	atctaataaa	3780
gtattttaatt	cagagtatga	gacaagacca	cttcgtaagt	gacactggag	atgttgttta	3840
ttatcagact	gattctctgc	tcctccactc	gcaacgagac	tgagtttcaa	actttttggg	3900
ttattattta	ttgattctag	ctactcaaat	tacttttttt	ttaatgttat	gttttttgga	3960
gtttaacgtt	ttctgaacaa	cttgcaaaatt	acttgcatag	agagacatgg		4010

<210> 4

<211> 192

<212> DNA

<213> Glycine max

<400> 4

gtaataattt	ttgtgtttct	tactcttttt	tttttttttt	tgtttatgat	atgaatctca	60
cacattgttc	tgttatgtca	tttcttcttc	atttggcttt	agacaactta	aatttgagat	120
ctttattatg	tttttgctta	tatggtaaag	tgattcttca	ttatttcatt	cttcattgat	180
tgaattgaac	ag					192

<210> 5

<211> 348

<212> DNA

<213> Glycine max

<400> 5

gttagttcat	actggctttt	ttgtttgttc	atttgtcatt	gaaaaaaaat	cttttgttga	60
ttcaattatt	tttatagtgt	gtttggaagc	ccgtttgaga	aaataagaaa	tcgcatctgg	120
aatgtgaaag	ttataactat	ttagcttcat	ctgtcgttgc	aagtctcttt	attgggttaa	180
tttttatagc	gtgctaggaa	acccattcga	gaaaataaga	aatcacatct	ggaatgtgaa	240
agttataact	gttagcttct	gagtaaacgt	ggaaaaacca	cattttggat	ttggaaccaa	300
attttatattg	ataaatgaca	accaaattga	ttttgatgga	ttttgcag		348

<210> 6

<211> 142

<212> DNA
<213> Glycine max

<400> 6	
gtatgtgatt aattgcttct cctatagttg ttcttgattc aattacattt tattttatttg	60
gtaggtccaa gaaaaaaggg aatctttatg ctctctgagg ctgttcttga acatggctct	120
tttttatgtg tcattatctt ag	142

<210> 7
<211> 1231
<212> DNA
<213> Glycine max

<400> 7	
gtaacaaaaa taaatagaaa atagtgggtg aacacttaaa tgcgagatag taatacctaa	60
aaaaagaaaa aaatataggt ataataaata atataacttt caaaataaaa agaaatcata	120
gagtcctagcg tagtggttgg agtgaaatga tggtcaccta ccattactca aagattttgt	180
tgtgtccctt agttcattct tattatttta catatcttac ttgaaaagac tttttaatta	240
ttcattgaga tcttaaagtg actgttaaat taaaataaaa aacaagtttg ttaaaacttc	300
aaataaataa gagtgaaggg agtgtcattt gtcttctttc ttttattgcg ttattaatca	360
cgtttctctt ctcttttttt tttttcttct ctgctttcca cccattatca agttcatgtg	420
aagcagtggc ggaatctatgt aaatgagtg ggggcaattg caccacaag attttatttt	480
ttatttgtag aggaataata aaataaaaact ttgcccccat aaaaaataaa tttttttct	540
taaaataatg caaaataaat ataagaaata aaaagagaat aaattattat taattttatt	600
attttgtact ttttatttag ttttttttagc ggtagattt ttttttcatg acattatgta	660
atcttttaaa agcatgtaat attttttattt tgtgaaaata aatataaatg atcatattag	720
tctcagaatg tataaaactaa taataatttt atcactaaaa gaaattctaa tttagtccat	780
aaataagtaa aacaagtgac aattatattt tatatttact taatgtgaaa taatacttga	840
acattataat aaaacttaat gacaggagat attacatagt gccataaaga ttttttaaaa	900
aataaaatca ttaatacact gtactactat ataatatctg atatatattt ttaacatgat	960
tctcaataga aaaattgtat tgattatatt ttattagaca tgaatttaca agccccgttt	1020
ttcatttata gctcttacct gtgatctatt gttttgcttc gctgtttttg ttgggtcaagg	1080
gacttagatg tcacaatatt aatactagaa gtaaaatatt atgaaaacat gtaccttacc	1140
tcaacaaaga aagtgtggta agtggcaaca cacgtgttgc atttttggcc cagcaataac	1200
acgtgttttt gtgggtgtact aaaatggaca g	1231

<210> 8
<211> 626
<212> DNA
<213> Glycine max

<400> 8	
gtacatttta ttgcttattc acctaaaaac aatacaatta gtacatttgt tttatctctt	60
ggaagttagt cattttcagt tgcattgatc taatgctctc tccattctta aatcatgttt	120
tcacaccacac ttcattttaa ataagaacgt ggggtgttatt ttaatttcta ttcactaaca	180
tgagaaatta acttattttca agtaataatt ttaaaatatt tttatgctat tattttatta	240
caaataatta tgtatattaa gtttattgat tttataataa ttatattaaa atttatcgga	300
tattaatttt tgattcactg atagtgtttt atattgttag tactgtgcat ttattttaaa	360
attggcataa ataatatatg taaccagctc actatactat actgggagct tgggtgggaa	420
aggggttccc aacctcctt tctaggtgta catgctttga tacttctggt accttcttat	480
atcaatataa atttatattt gctgataaaa aaacatggtt aaccattaaa ttcttttttt	540
aaaaaaaaa ctgtatctaa actttgtatt attaaaaaga agtctgagat taacaataaa	600
ctaaactca tttggattca ctgcag	626

<210> 9

<211> 18
<212> DNA
<213> SyntheticArtificial Sequence

<220>
<223> Synthetic Oligonucleotide

<400> 9
atacaagcca ctaggcat 18

<210> 10
<211> 26
<212> DNA
<213> Artificial Sequence

<220>
<223> Synthetic Oligonucleotide

<400> 10
gattggccat gcaatgaggg aaaagg 26

<210> 11
<211> 37
<212> DNA
<213> Artificial Sequence

<220>
<223> Synthetic Oligonucleotide

<400> 11
cuacuacuac uactcgagac aaagccttta gcctatg 37

<210> 12
<211> 36
<212> DNA
<213> Artificial Sequence

<220>
<223> Synthetic Oligonucleotide

<400> 12
caucauauca auggatccca tgtctctcta tgcaag 36

<210> 13
<211> 34
<212> DNA
<213> Artificial Sequence

<220>
<223> Synthetic Oligonucleotide

<400> 13
acgaattcct cgaggtaaata taaattgtgc ctgc 34

<210> 14

<211> 33
<212> DNA
<213> Artificial Sequence

<220>
<223> Synthetic Oligonucleotide

<400> 14
gcgagatcta tcgatctgtg tcaaagtata aac 33

<210> 15
<211> 30
<212> DNA
<213> Artificial Sequence

<220>
<223> Synthetic Oligonucleotide

<400> 15
gatcgatgcc cggggtaata atttttgtgt 30

<210> 16
<211> 29
<212> DNA
<213> Artificial Sequence

<220>
<223> Synthetic Oligonucleotide

<400> 16
cacgcctcga gtgttcaatt caatcaatg 29

<210> 17
<211> 24
<212> DNA
<213> Artificial Sequence

<220>
<223> Synthetic Oligonucleotide

<400> 17
cactcgagtt agttcatact ggct 24

<210> 18
<211> 25
<212> DNA
<213> Artificial Sequence

<220>
<223> Synthetic Oligonucleotide

<400> 18
cgcatcgatt gcaaaatcca tcaaa 25

<210> 19

<211> 38
 <212> DNA
 <213> Artificial Sequence

<220>
 <223> Synthetic Oligonucleotide

<400> 19
 cuacuacuac uactcgagcg taaatagtgg gtgaacac 38

<210> 20
 <211> 41
 <212> DNA
 <213> Artificial Sequence

<220>
 <223> Synthetic Oligonucleotide

<400> 20
 caucauac auctcgagga attcggtccat ttagtagacac c 41

<210> 21
 <211> 39
 <212> DNA
 <213> Artificial Sequence

<220>
 <223> Synthetic Oligonucleotide

<400> 21
 cuacuacuac uactcgaggc gcgtacattt tattgctta 39

<210> 22
 <211> 41
 <212> DNA
 <213> Artificial Sequence

<220>
 <223> Synthetic Oligonucleotide

<400> 22
 caucauac auctcgagga attctgcagt gaatccaaat g 41

<210> 23
 <211> 1734
 <212> DNA
 <213> Glycine max

<400> 23
 .actatagggc acgcgtgggc gacggcccgg gctggtcctc ggtgtgactc agccccaagt 60
 gacgccaacc aaacgcgtcc taactaaggt gtagaagaaa cagatagtat ataagtatac 120
 catataagag gagagtgagt ggagaagcac ttctcctttt tttttctctg ttgaaattga 180
 aagtgttttc cgggaaataa ataaaataaa ttaaaatctt acacactcta ggtaggtact 240
 tctaatttaa tccacacttt gactctatat atgtttttaa aataattata atgcgtactt 300
 acttcctcat tataactaat ttaacatcga tgattttatt ttctgtttct cttctttcca 360

cctacataca	tcccaaaatt	taggggtgcaa	ttttaagttt	attaacacat	gttttttagct	420
gcatgctgcc	tttggtgtgtg	ctcaccaaatt	tgcatctctc	tctttatatg	ttgtatttga	480
attttcacac	catatgtaaa	caagattacg	tacgtgtcca	tgatcaaata	caaagtgtgt	540
cttatactgg	caatttgata	aacagccgtc	cattttttct	ttttctcttt	aactatatat	600
gctctagaat	ctctgaagat	tcctctgcca	tcgaatttct	ttcttggttaa	caacgtcgtc	660
gttatgttat	tattttattc	tatttttatt	ttatcatata	tatttcttat	tttggtcgaa	720
gtatgtcata	ttttgatcgt	gacaattaga	ttgtcatgta	ggagtaggaa	tatcacttta	780
aaacattgat	tagtctgtag	gcaatattgt	cttctttttc	ctcctttatt	aatatatttt	840
gtcgaagttt	taccacaagg	ttgattcgct	ttttttgtcc	ctttctcttg	ttctttttac	900
ctcagggtatt	ttagtctttc	atggattata	agatcactga	gaagtgtatg	catgtaatac	960
taagcaccat	agctgttctg	cttgaattta	tttggtgtga	aattgtaatg	tttcagcggt	1020
ggctttccct	gtagctgcta	caatgggtact	gtatatctat	tttttgcatt	gttttcattt	1080
tttctttttac	ttaatcttca	ttgctttgaa	attaataaaa	caatataata	tagtttgaac	1140
tttgaactat	tgccatttca	tgtaattaac	ttattcactg	actcttattg	tttttctggt	1200
agaattcatt	ttaaattgaa	ggataaatta	agaggcaata	cttgtaaatt	gacctgtcat	1260
aattacacag	gaccctgttt	tgtgcctttt	tgtctctgtc	tttggttttg	catgttagcc	1320
tcacacagat	atttagtagt	tgttctgcat	acaagcctca	cacgtatact	aaaccagtgg	1380
acctcaaagt	catggcctta	cacctattgc	atgcgagctc	gtgacacaac	ccctggtttc	1440
catattgcaa	tgtgctacgc	cgtcgtcctt	gtttgtttcc	atatgtatat	tgataccatc	1500
aaattattat	atcattttata	tggtctggac	cattacgtgt	actctttatg	acatgtaatt	1560
gagtttttta	attaaaaaaa	tcaatgaaat	ttaactacgt	agcatcatat	agagataatt	1620
gactagaaat	ttgatgactt	attctttcct	aatcatattt	tcttgtattg	atagccccgc	1680
tgtccctttt	aaactcccga	gagagtataa	aactgcatcg	aatattacaa	gatg	1734

<210> 24
 <211> 405
 <212> DNA
 <213> Glycine max

<400> 24						
gtatgatgct	aaattaaatt	gtgcctgcac	cccaggatat	ttcatgtggg	attcatcatt	60
tattgaggaa	aactctccaa	attgaatcgt	gcattttatat	tttttttcca	tttctagatt	120
tcttgaaggc	ttatggtata	ggcacctaca	attatcagca	cttctctcta	ttgataaaca	180
attggctgta	ataccacagt	agagaacgat	cacaacattt	tgtgctgggt	accttttggt	240
ttatgggtcat	gatttcactc	tctctaattc	gtcacttccc	tccattcatt	ttgtacttct	300
catattttttc	acttccctgg	tgaataattgt	agttctcttg	gtacatacta	gtatttagaca	360
ttcagcaaca	acaactgaac	tgaacttctt	tatactttga	cacag		405

<210> 25
 <211> 98
 <212> DNA
 <213> Glycine max

<400> 25						
gtgagtgatt	ttttgacttg	gaagacaaca	acacattatt	attataatat	ggttcaaaac	60
aatgactttt	tctttatgat	gtgaactcca	tttttttag			98

<210> 26
 <211> 115
 <212> DNA
 <213> Glycine max

<400> 26						
gtaactaaat	tactcctaca	ttgttacttt	ttcctccttt	tttttattat	ttcaattctc	60
caattggaaa	tttgaaatag	ttaccataat	tatgtaattg	tttgatcatg	tgag	115

<210> 27
 <211> 778
 <212> DNA
 <213> Glycine max

<220>
 <221> misc_feature
 <222> (1)...(778)
 <223> n = A,T,C or G

<400> 27
 atacaagcca ctaggcatgg taaattaaat tgtgcctgca cctcgggata tttcatgtgg 60
 gggtcatcat atttggtgag gaaaagaaac tcccgaatt gaattatgca tttatatatc 120
 ctttttcatt tctagatttc ctgaaggctt aggtgtaggc acctagctag tagctacaat 180
 atcagcactt ctctctattg ataaacaatt ggctgtaatg ccgcagtaga ggacgatcac 240
 aacatttcgt gctgggtact ttttgtttta tgggtcatgat ttcactctct ctaatctctc 300
 cattcatttt gtagttgtca ttatcttttag atttttctact acctgggtta aaattgaggg 360
 attgtagttc tggttgtaca tattacacat tcagcaaaac aactgaaact caactgaact 420
 tgtttatact ttgacacagg gtctagcaaa ggaaacaaca atgggaggta gaggtcgtgt 480
 ggccaaagtg gaagttcaag ggaagaagcc tctctcaagg gttccaaaca caaagccacc 540
 attcactggt ggccaactca agaaagcaat tccaccacac tgctttcagc gtcacctcct 600
 cacttcattc tcctatgttg tttatgacct ttcatttgcc ttcattttct acattgccac 660
 caactacttc cacctccttc ctcaaccctt ttccctcatt gcatggccaa tcaagccgaa 720
 ttctgcagat atccatcaca tggcggcggg tggngnaggn ntntanaggg cccaattc 778

<210> 28
 <211> 148
 <212> DNA
 <213> Glycine max

<400> 28
 gtaatctcac tctcacactt tctttatata tcgcacacca gtgtgggtta tttgcaacct 60
 acaccgaagt aatgccctat aattaatggg gttaacacat gtccaagtcc aatattttgt 120
 tcacttattt gaacttgaac atgtgtag 148

<210> 29
 <211> 361
 <212> DNA
 <213> Glycine max

<400> 29
 gtatcccatt taacacaatt tgtttcatta acattttaag agaatttttt tttcaaaata 60
 gttttcgaaa ttaagcaaat accaagcaaa ttgttagatc tacgcttgta cttgttttaa 120
 agtcaaattc atgaccaaatt tgtcctcaca agtccaaacc gtccactatt ttattttcac 180
 ctactttata gcccaatttg tcatttggtt acttcagaaa agagaacccc atttgtagta 240
 aatatattat ttatgaatta tggtagtttc aacataaaac atatttatgt gcagttttgc 300
 catccttcaa aagaagatag aaacttactc catgttactc tgtctatatg taatttcaca 360
 g 361

<210> 30
 <211> 36
 <212> DNA
 <213> Glycine max

<400> 30
gcgatcgatg tatgatgcta aattaaattg tgcctg 36

<210> 31
<211> 30
<212> DNA
<213> Glycine max

<400> 31
gcggaattcc tgtgtcaaag tataaagaag 30

<210> 32
<211> 19
<212> DNA
<213> Glycine max

<400> 32
catgctttct gtgcttctc 19

<210> 33
<211> 19
<212> DNA
<213> Glycine max

<400> 33
gttgatccaa ccatagtcg 19

(19) World Intellectual Property Organization
International Bureau



(43) International Publication Date
1 March 2001 (01.03.2001)

PCT

(10) International Publication Number
WO 01/14538 A3

- (51) International Patent Classification⁷: C12N 15/82, 9/02, C07K 14/415, A01H 5/00
- (21) International Application Number: PCT/US00/22613
- (22) International Filing Date: 11 August 2000 (11.08.2000)
- (25) Filing Language: English
- (26) Publication Language: English
- (30) Priority Data:
60/151,224 26 August 1999 (26.08.1999) US
60/172,128 17 December 1999 (17.12.1999) US
- (71) Applicant: CALGENE LLC [US/US]; 1920 Fifth Street, Davis, CA 95616 (US).
- (72) Inventor: FILLATTI, Joanne, J.; 36757 Russell Blvd., Davis, CA 95616 (US).
- (74) Agent: EAGLE, Alissa, M.; Calgene LLC, 1920 Fifth Street, Davis, CA 95616 (US).
- (81) Designated States (*national*): AL, AM, AT, AU, AZ, BA, BB, BG, BR, BY, CA, CH, CN, CU, CZ, DE, DK, EE, ES, FI, GB, GD, GE, GH, GM, HR, HU, ID, IL, IN, IS, JP, KE, KG, KP, KR, KZ, LC, LK, LR, LS, LT, LU, LV, MD, MG, MK, MN, MW, MX, NO, NZ, PL, PT, RO, RU, SD, SE, SG, SI, SK, SL, TJ, TM, TR, TT, UA, UG, UZ, VN, YU, ZW.
- (84) Designated States (*regional*): European patent (AT, BE, CH, CY, DE, DK, ES, FI, FR, GB, GR, IE, IT, LU, MC, NL, PT, SE).
- Published:
— with international search report
- (88) Date of publication of the international search report:
20 September 2001
- For two-letter codes and other abbreviations, refer to the "Guidance Notes on Codes and Abbreviations" appearing at the beginning of each regular issue of the PCT Gazette.*

(54) Title: PLANTS WITH MODIFIED POLYUNSATURATED FATTY ACIDS

(57) Abstract: By this invention, novel nucleic acid sequences are provided, wherein said nucleic acid sequence is a genomic sequence of a plant desaturase encoding sequence. Also provided in the present invention are the promoter and intron sequences of the desaturase genomic sequences. Furthermore, recombinant DNA constructs employing the polynucleotide sequences are provided. The instant invention also provides methods for the modification of fatty acid compositions in host plant cells.

WO 01/14538 A3

INTERNATIONAL SEARCH REPORT

International Application No

PC1/US 00/22613

A. CLASSIFICATION OF SUBJECT MATTER

IPC 7 C12N15/82 C12N9/02 C07K14/415 A01H5/00

According to International Patent Classification (IPC) or to both national classification and IPC

B. FIELDS SEARCHED

Minimum documentation searched (classification system followed by classification symbols)

IPC 7 C12N C07K

Documentation searched other than minimum documentation to the extent that such documents are included in the fields searched

Electronic data base consulted during the international search (name of data base and, where practical, search terms used)

EPO-Internal, WPI Data, PAJ, BIOSIS, MEDLINE, STRAND

C. DOCUMENTS CONSIDERED TO BE RELEVANT

Category *	Citation of document, with indication, where appropriate, of the relevant passages	Relevant to claim No.
X	WO 94 11516 A (DU PONT ;LIGHTNER JONATHAN EDWARD (US); OKULEY JOHN JOSEPH (US)) 26 May 1994 (1994-05-26) the whole document	1,13,16, 19-31, 33-35, 37-41, 43-48
X	WO 93 11245 A (DU PONT) 10 June 1993 (1993-06-10) see SEQ ID NO: 10 page 19 -page 20; claims 1-18; examples 5,13-15 -/--	3,17, 20-31, 33-35, 37-41, 43-48



Further documents are listed in the continuation of box C.



Patent family members are listed in annex.

* Special categories of cited documents:

- *A* document defining the general state of the art which is not considered to be of particular relevance
- *E* earlier document but published on or after the international filing date
- *L* document which may throw doubts on priority claim(s) or which is cited to establish the publication date of another citation or other special reason (as specified)
- *O* document referring to an oral disclosure, use, exhibition or other means
- *P* document published prior to the international filing date but later than the priority date claimed

- *T* later document published after the international filing date or priority date and not in conflict with the application but cited to understand the principle or theory underlying the invention
- *X* document of particular relevance: the claimed invention cannot be considered novel or cannot be considered to involve an inventive step when the document is taken alone
- *Y* document of particular relevance: the claimed invention cannot be considered to involve an inventive step when the document is combined with one or more other such documents, such combination being obvious to a person skilled in the art
- *&* document member of the same patent family

Date of the actual completion of the international search

16 March 2001

Date of mailing of the international search report

26/04/2001

Name and mailing address of the ISA

European Patent Office, P.B. 5818 Patentlaan 2
NL - 2280 HV Rijswijk
Tel (+31-70) 340-2040, Tx. 31 651 epo nl,
Fax: (+31-70) 340-3016

Authorized officer

Oderwald, H

INTERNATIONAL SEARCH REPORT

International Application No

PCT/US 00/22613

C.(Continuation) DOCUMENTS CONSIDERED TO BE RELEVANT

Category *	Citation of document, with indication, where appropriate, of the relevant passages	Relevant to claim No.
X	US 5 850 026 A (DEBONTE LORIN R ET AL) 15 December 1998 (1998-12-15) the whole document ---	30,31, 33-35, 37-41, 43-48
X	CARTEA M E ET AL: "COMPARISON OF SENSE AND ANTISENSE METHODOLOGIES FOR MODIFYING THE FATTY ACID COMPOSITION OF ARABIDOPSIS THALIANA OILSEED" PLANT SCIENCE, LIMERICK, IE, vol. 136, no. 2, 1998, pages 181-194, XP000946335 ISSN: 0168-9452 the whole document ---	30,31, 33-35, 37-41, 43-48
X	OKULEY J ET AL: "ARABIDOPSIS FAD2 GENE ENCODES THE ENZYME THAT IS ESSENTIAL FOR POLYUNSATURATED LIPID SYNTHESIS" PLANT CELL, US, AMERICAN SOCIETY OF PLANT PHYSIOLOGISTS, ROCKVILLE, MD, vol. 6, 1994, pages 147-158, XP002034147 ISSN: 1040-4651 the whole document ---	30,31, 33-35, 40,41
X	DATABASE EM_GSS 'Online! EMBL Heidelberg, Germany; AC AL071390, 29 May 1999 (1999-05-29) GENOSCOPE: "Drosophila melanogaster genome survey sequence TET3 end of BAC: BACR32M05" XP002163063 abstract ---	2,20-22
X	DATABASE EMPLN 'Online! EMBL Heidelberg, Germany; AC/ID AC004705, 21 May 1998 (1998-05-21) LIN X ET AL.: "Sequence and analysis of chromosome 2 of the plant Arabidopsis thaliana" XP002163064 see nucleotides 76.500 to 76.700 abstract ---	4,20-22
X	DATABASE EM_GSS 'Online! EMBL Heidelberg, Germany; AC AL105179, 26 July 1999 (1999-07-26) GENOSCOPE: "Drosophila melanogaster genome survey sequence T7 end of BAC: BACN13A12" XP002163065 abstract ---	5,20-22
	--- -/--	

INTERNATIONAL SEARCH REPORT

International Application No

PCT/US 00/22613

C.(Continuation) DOCUMENTS CONSIDERED TO BE RELEVANT

Category *	Citation of document, with indication, where appropriate, of the relevant passages	Relevant to claim No.
X	<p>DATABASE EM_NEW 'Online! EMBL Heidelberg, Germany; AC/ID AB022220, 15 January 1999 (1999-01-15) SATO S ET AL.: "Arabidopsis thaliana genomic DNA, chromosome 3, P1 clone: MLN21" XP002163066 abstract</p>	6,20-22
X	<p>DATABASE EM_GSS 'Online! EMBL Heidelberg, Germany; AC AL069706, 29 May 1999 (1999-05-29) GENOSCOPE: "Drosophila melanogaster genome survey sequence T7 end of BAC: BACR29B23" XP002163067 abstract</p>	7,20-22
X	<p>CLARK-WALKER G D ET AL: "LOCATION OF TRANSCRIPTIONAL CONTROL SIGNALS AND TRANSFER RNA SEQUENCES IN TORULOPSIS-GLABRATA MITOCHONDRIAL DNA" EMBO (EUROPEAN MOLECULAR BIOLOGY ORGANIZATION) JOURNAL, vol. 4, no. 2, 1985, pages 465-473, XP002163062 ISSN: 0261-4189 the whole document</p>	8,20-22
X	<p>DATABASE EM_GSS 'Online! EMBL Heidelberg, Germany; AC AL063932, 29 May 1999 (1999-05-29) GENOSCOPE: "Drosophila melanogaster genome survey sequence TET3 end of BAC: BACR8010" XP002163068 abstract</p>	9,20-22
X	<p>DATABASE EM_GSS 'Online! EMBL Heidelberg, Germany; AC AL108811, 26 July 1999 (1999-07-26) GENOSCOPE: "Drosophila melanogaster genome survey sequence SP6 end of BAC BACN37D10" XP002163069 abstract</p>	10,20-22
X	<p>DATABASE EM_NEW 'Online! EMBL Heidelberg, Germany; AC/ID AB026636, 7 May 1999 (1999-05-07) SATO S ET AL.: "Arabidopsis thaliana genomic DNA, chromosome 3, TAC clone:K14A17" XP002163070 see nucleotides 57.700 to 57.810 abstract</p>	11,20-22

-/--

INTERNATIONAL SEARCH REPORT

International Application No

PCT/US 00/22613

C.(Continuation) DOCUMENTS CONSIDERED TO BE RELEVANT

Category *	Citation of document, with indication, where appropriate, of the relevant passages	Relevant to claim No.
X	WO 98 30083 A (UNIV CALIFORNIA) 16 July 1998 (1998-07-16) see nucleotides 6.450 to 6.570 of SEQ ID NO: 89 (RG2B; p. 110-117) abstract; claims 1-5,8,9,18-30,32,37,41-54; examples 1,4 page 2 -page 43 ---	14, 20-24, 30,31
P,X	DATABASE EMBL_PLN 'Online! EMBL Heidelberg, Germany; AC/ID AW397948, 8 February 2000 (2000-02-08) SHOEMAKER R ET AL.: "Public soybean EST project" XP002163071 abstract ---	2,10,13, 20
P,X	DATABASE EMBL_PLN 'Online! EMBL Heidelberg, Germany; AC AL161581, 16 March 2000 (2000-03-16) WEICHSELGARTNER M ET AL.: "Arabidopsis thaliana chromosome 4, contig fragment No. 77" XP002163072 see nucleotides 70600 to 70700 abstract -----	9,20

INTERNATIONAL SEARCH REPORT

Information on patent family members

International Application No

PCT/US 00/22613

Patent document cited in search report	Publication date	Patent family member(s)	Publication date
WO 9411516 A	26-05-1994	AU 5407594 A	08-06-1994
		AU 6984198 A	01-10-1998
		CA 2149223 A	26-05-1994
		EP 0668919 A	30-08-1995
		JP 8503364 T	16-04-1996
WO 9311245 A	10-06-1993	AU 675923 B	27-02-1997
		AU 3228893 A	28-06-1993
		CA 2124673 A	10-06-1993
		EP 0616644 A	28-09-1994
		JP 7501701 T	23-02-1995
		US 5952544 A	14-09-1999
US 5850026 A	15-12-1998	US 6063947 A	16-05-2000
WO 9830083 A	16-07-1998	EP 0969714 A	12-01-2000